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ABSTRACT 
 
 
MONOCYTE/MACROPHAGE TRAFFIC PLAYS AN  
ESSENTIAL ROLE IN HIV AND SIV PATHOGENESIS  
 
 
Author: Jennifer H. Campbell  
 
 
Advisor: Kenneth C. Williams, Ph.D. 
 
 
Elucidating the mechanisms through which viral infection and persistence 
in CNS occurs is critical to understanding the development and progression of 
neurological disease.  To date, no study has demonstrated that monocyte traffic 
in HIV and SIV infection directly results in neuronal injury.  The central 
hypothesis in this thesis is that continuous trafficking of monocytes into tissues is 
essential for pathogenesis with viral infection.  In the dissertation work presented 
here, two studies addressed this hypothesis.  In Chapter 2, experiments 
examining the role of peripheral monocyte activation in the development of 
neuroAIDS using the tetracycline antibiotic minocycline will be described. We 
hypothesized that decreased monocyte activation with minocycline treatment 
would play a neuroprotective role in the context of rapid SIV infection with a high 
incidence of SIV encephalitis (SIVE).   We observed a reversal of neuronal injury 
within days of minocycline treatment that correlated with loss of monocyte 
activation.  From these findings we concluded that decreased activation of 
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monocytes results in lower CNS traffic.  However this effect may have occurred 
due to lower plasma virus, decreased SIV infection of monocytes, or the ability of 
minocycline to cross the BBB and modulate changes within the CNS directly.   
In Chapter 3 of this thesis, we hypothesized that continuous traffic of 
activated monocytes from the periphery into the CNS is required for neuronal 
injury with AIDS, and that by effectively stopping monocyte accumulation, CNS 
pathology can be blocked or reversed.  We also hypothesized that monocyte 
trafficking is necessary for the seeding of brain and small intestine with cell-
associated virus.  In order to test these hypotheses, we utilized the anti-α4 
blocking antibody natalizumab (Tysabri; Biogen Idec), which selectively binds to 
the α4 subunit of α4β1 (VLA-4) and α4β7 integrins, preventing the interaction 
between α4 and its various ligands.  To address the first hypothesis, natalizumab 
was administered after four weeks of infection once significant neuronal damage 
had already occurred.  We found that preventing cell traffic with natalizumab is 
sufficient to stabilize neuronal injury and loss, demonstrating conclusively that 
stopping monocyte traffic stabilizes CNS disease.  To address the second 
hypothesis, rhesus macaques were treated with natalizumab on the day of SIV 
infection.  Natalizumab treatment completely blocked SIV infection in the brain, 
and virus traffic to the small intestine was significantly suppressed.  Overall, 
these studies demonstrate that continuous traffic of monocytes is required for 
neuronal injury and the formation of CNS lesions, and that early trafficking of 
leukocytes is critical for seeding of the CNS and contributes to seeding of the 
small intestine with virus.  
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LITERATURE REVIEW 
 
 
I.  Human Immunodeficiency Virus   
A.  An annotated history of HIV and AIDS  
The Human Immunodeficiency Virus (HIV) pandemic continues to be a 
monumental challenge for research, public health, and medicine.  Since HIV was 
first identified more than thirty years ago, it is estimated that ~ 59 million people 
have become infected, with over 25 million deaths resulting from complications of 
the disease [1].  Retrospective sequence analyses have demonstrated that an 
individual in Africa was infected with HIV as early as 1959 [2], however the virus 
quietly spread around the world from the 1960’s until 1981, when several cases 
of Pneumocystis carinii pneumonia and Kaposi’s Sarcoma were reported across 
the United States in a short period of time [3,4].  The severe lymphopenia and 
immune suppression observed in these individuals was described as acquired 
immune deficiency syndrome (AIDS) by the Centers for Disease Control before 
the end of 1981 [5].  A few years later, the first human retrovirus was isolated 
from patients with AIDS [6], prompting intense research into the etiology and role 
of viral infection in immune deterioration.  The virus was first termed human T-
cell leukemia virus (HTLV) – I, and HTLV II and III were also described before 
researchers demonstrated that this retrovirus caused AIDS [7,8], and 
appropriately named the virus HIV [9].  Around the same time, a systematic 
description of central nervous system (CNS) complications with AIDS were 
initially described as subacute encephalitis [10], which was later termed HIV-
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associated dementia (HAD) [11].  In 1987, based on promising changes in viral 
load and CD4+ T cell count, azidothymidine (AZT) was rapidly approved as the 
first anti-retroviral drug for the treatment of AIDS [12], however it was soon 
evident that there was little improvement in the time to death with this medication.  
Nearly a decade later, highly active antiretroviral therapy (HAART) was 
introduced and immediately resulted in improved clinical outcomes relative to 
patients on monotherapies [13-15].  Since then, great strides have been made in 
the treatment of HIV.  There are currently 27 antiretroviral drugs on the market in 
the United States [16], that when used in combinations of 3 or more (combination 
antiretroviral therapy, cART), significantly improve the longevity of HIV-infected 
individuals [17,18].  
B. HIV Transmission and clinical features of HIV infection  
Mucosal exposure remains the primary route of HIV transmission, 
accounting for approximately 80% of new infections worldwide [19].  The other 
20% result from percutaneous/intravenous infection or mother to infant 
transmission [20].  There are several well-characterized periods in the course of 
HIV infection: (1) an early asymptomatic phase of uncontrolled viral spread 
around the body until ~2 weeks post infection (wpi), (2) acute infection and 
viremia within 2-4 wpi, (3) a period of virologic latency lasting an average of 10 
years, and (4) progression to AIDS, which occurs in the absence of cART, or 
upon treatment failure [21] (Figure 1.1).    
Viral infection begins with attachment of the envelope glycoprotein gp120 
portion of the gp120/gp41 heterotrimeric protein to the CD4 receptor on the host  
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cell [22,23].  Once the virus has bound to the host cell, conformational changes 
in gp120 allow it to form additional interactions with co-receptors C-C chemokine 
receptor type 5 (CCR5) and/or C-X-C chemokine receptor type 4 (CXCR4).  
During acute disease, virions initially target leukocytes expressing CD4 and 
CCR5, including monocytes, macrophages, dendritic cells, and T cells [19].  Over 
time, HIV evolves to also utilize CXCR4 for infection of target cells [24].   
 
 
 
 
 
 
 
 
 
 
 
 
               Prior to cART or in 
               the absence of 
               effective therapy 
 
 
Figure 1.1  Pathogenesis of HIV infection.  A schematic diagram of the 
pathogenic effects that occur from initial infection with HIV through the 
development of clinical disease.  (Modified from Pantaleo and Fauci, 
Current Opinion in Immunology 1994) 
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Binding of gp120 to its’ co-receptor results in insertion of the gp41 fusion peptide 
into the host cell membrane [25].  This allows the viral core, including the 
genome, reverse transcriptase, and integrase, to be released into the cytoplasm 
[26].  Uncoating of the viral core during transport from the cytoplasm to the 
nucleus facilitates the formation of the pre-integration complex [27,28].  Once in 
the nucleus, the integrase protein incorporates the viral genome into the host 
cellular DNA, where it can now be used as a template for the production of new 
virions [29].  Integration occurs within hours of infection, and once integrated, the 
provirus persists throughout the life of the host cell [30].  Initiation of replication 
requires interaction between the transcriptional activator protein tat and the 
transactivation response (TAR) RNA element [31], which together promote 
recruitment of the positive transcription elongation factor P-TEFb [32].  Direct 
binding of tat to P-TEFb results in phosphorylation of RNA polymerase [33], 
marking the transition from initiation of HIV replication to transcript elongation 
[34].  With the help of other viral and cellular proteins, HIV RNA is spliced, 
transported, translated, and assembled into virions [35].  Finally, particles bud 
from the cell surface and HIV protease activity renders newly formed virions 
infectious, completing a full cycle of HIV replication in 1-2 days [36].  During 
reverse transcription HIV replicates and mutates frequently, which, over time 
leads to high levels of variation in the viral sequence and ultimately diminishes 
the potential of current antiretroviral interventions [37].  Based on mathematical 
models, activated CD4+ T lymphocytes produce the majority of viral particles, 
however these cells are short-lived, surviving for approximately a day after 
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becoming infected [38].  In contrast, infection with HIV is not lytic to monocytes 
and macrophages [39], and allows these cells to produce virions and harbor 
provirus long-term [40,41].  
Regardless of the route of transmission, productive viral replication 
typically occurs first in the draining lymph nodes, and from there infected 
leukocytes travel through the bloodstream to the gut, brain, spleen, liver, lungs, 
and bone marrow, which promotes an exponential expansion of infected cells 
throughout the body [42] (Figure 1.2).   
 
 
 
 
                     Hours 
 
 
                       1-3 dpi 
 
 
 
                      3-7 dpi 
 
 
              
 
                      > 7 dpi 
 
               
                        
 
 
 
Figure 1.2  HIV-1 transmission and acute infection.  Preferential CCR5 HIV 
transmission is illustrated along with potential roles for macrophages and 
dendritic cells. Virus-host cell interactions in the initial days of infection have 
been elucidated primarily in SIV-infected rhesus macaques.  (Adapted from 
Shaw and Hunter, Cold Spring Harbor Perspectives in Medicine 2012) 
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The gut-associated lymphoid tissue (GALT) harbors <90% of the body’s 
lymphocytes, macrophages, and dendritic cells [43,44], and the majority of these 
cells express the viral co-receptor CCR5 [45,46].  During the early asymptomatic 
phase of disease, this pool of activated leukocytes is preferentially infected and 
provides HIV with an ideal environment for viral replication [47,48], leading to 
severe CD4+ T lymphocyte depletion in the gastrointestinal (GI) tract [49,50].  
Changes in the intestinal epithelium are also evident soon after exposure to HIV, 
including breakdown of the mucosa that prompts translocation of 
lipopolysaccharide (LPS) and other bacterial products into the blood [51,52].  
Increased production of inflammatory cytokines and chemokines including 
interferon alpha (IFN-α), interferon gamma (IFN-γ), interleukin 15 (IL-15), tumor 
necrosis factor (TNF)-α, monocyte chemotactic protein (MCP)-1, IL-6, IL-8, and 
CXCL10, as well as the expansion of CD4+ T lymphocytes in the blood occur 
within the first days to weeks after infection, and aid in further dissemination of 
virus throughout the body [53,54].  This results in high plasma viremia (≥ 107 
copies of HIV RNA per mL of blood) [55,56], which is frequently accompanied by 
the earliest clinical signs of HIV infection, such as fever, fatigue, rash, sore 
throat, swollen lymph nodes, and flu-like symptoms [57-59].  Intriguingly, GI 
symptoms are not typically reported during this time [60].  With peak viremia, 
HIV-specific cytotoxic CD8+ T lymphocytes (CTLs) start to develop and 
contribute to the initial decline in plasma viral load [61,62].  About 3 months after 
exposure, the CTL response and neutralizing antibodies contribute to the control 
of viral replication [63].  At this point, an individuals’ set-point for viremia is  
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established, beginning the asymptomatic phase of disease [64].  Over time, HIV 
progressively destroys the immune system, leading to the transient depletion of 
the CD4+ T cells necessary to control the types of opportunistic infections (OIs) 
that are typically non-pathogenic to healthy individuals.  Once numbers of CD4+ 
T lymphocytes fall below ~200 cells per microliter of blood, the immune system 
can no longer fight adventitious infections or the virus itself, signaling the onset of 
AIDS.  In the absence of effective memory cells, there is recrudescence of 
plasma viremia and development of OIs, resulting in progression to AIDS and 
ultimately death of the infected individual (Figure 1.3).        
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3  Time course of typical HIV.  Patterns of CD4+ T cell decline and 
viremia vary greatly from one patient to another.  (Modified from Coffin and 
Swanstrom, Cold Spring Harbor Perspectives in Medicine 2013) 
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C.  HIV infection in the cART era   
Fortunately, the advent of cART has greatly improved the health of HIV 
infected individuals.  When an appropriate drug regimen is found and if 
adherence is good, patients can exhibit improved immune function and suppress 
plasma virus to levels below the threshold of clinical detection (50 copies of HIV 
RNA/mL of plasma) for several years [65].  Yet, despite living longer with HIV 
infection, individuals are at a much higher risk of developing non-AIDS related 
cancers, kidney, liver, cardiovascular, gastrointestinal, and neurologic diseases 
than their age-matched HIV-negative counterparts [66].  The reasons for this 
increased susceptibility are not fully understood, however it appears that chronic 
inflammation and immune dysfunction with HIV infection are likely at the root of 
these pathologies.  As more than 33 million people around the world are currently 
living with HIV, it is evident that cART alone is not sufficient to rid the body of 
virus [67].  Therefore, it is imperative that predictive biological markers, 
underlying causes, and ultimately improved therapies for these increasingly 
prevalent co-morbidities be more closely explored. 
Gastrointestinal manifestations of HIV infection with cART  
Even when cART is initiated very early in infection there is irreversible 
damage to the gut, as lymphocytes in the small intestine get depleted by 2 wpi 
[68,69] before HIV is detected in the blood, and because it is difficult for most 
drugs to cross into the GI tract [70].  The GALT remains CD4+ T lymphocyte 
depleted throughout the course of HIV infection [49], and residual translocation of 
LPS across the gut mucosa is positively correlated with ongoing levels of 
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peripheral immune activation and inefficient CD4+ T cell recovery in cART 
treated individuals [56,71-73].  In addition, after almost a decade of cART 
therapy, concentrations of HIV DNA in the gut remain unchanged despite 
complete suppression of virus in plasma [74,75].  As a result, GI symptoms and 
complications such as dysbiosis, diarrhea, nutrient malabsorption, weight loss, 
abdominal pain, and intestinal bleeding persist in the majority of cART treated 
patients [76-78].  Persistent inflammation and immune dysfunction may be the 
root of these pathologies, and events occurring during the acute phase of HIV 
infection are likely critical for determining the overall course and severity of 
disease.  Notably, chronic immune activation has also been repeatedly 
associated with monocyte expansion, disease progression, and the severity of 
neurological complications in HIV+ patients [79-83]. 
Neurological manifestations of HIV infection with cART  
Prior to widespread antiretroviral use, many HIV-infected individuals were 
developing HAD and corresponding neuropathology, or HIV encephalitis (HIVE).  
In the cART era the incidence of HAD has declined, however the prevalence of 
milder forms of HIV-associated neurocognitive disorders (HANDs) continues to 
increase [84].  Data published within the last year indicates that almost a third of 
HIV+ individuals with long-term viral suppression report significant deficits in 
cognitive and motor domains, and that more than 50% of patients meet formal 
criteria for HAND [85,86].  HAND diagnoses are based on deficiencies in motor 
skills, attention, and memory performance.  These disorders fall along a 
spectrum of severity from asymptomatic neurocognitive impairment (ANI), 
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through mild neurocognitive disorder (MND), to the most severe CNS 
involvement with HAD [87].  Importantly, development of HANDs are repeatedly 
associated with higher rates of AIDS-defining illnesses [88] as well as increased 
mortality [89] (Figure 1.4).  Some reports indicate that cognitive impairment is 
improved if individuals begin treatment early in the course of HIV infection [90-
92].     
 
 
 
 
 
 
 
 
Figure 1.4  Changes in the prevalence of HIV-associated brain disorders 
and survival in the eras pre-cART and post-cART.  The predominant 
transition since the introduction of potent combination antiretroviral therapies 
(cART) has been a replacement of HAD and MND by a milder, chronic 
asymptomatic neurocognitive impairment (ANI), with which individuals can live 
for many years.  The impact of a neurocognitive disorder that is severe in a 
patient who lives for a relatively short period of time might actually be less than 
the impact of a milder cognitive disorder in an individual who lives for decades.  
Question marks denote uncertainty as to the longevity of cART-treated 
individuals.  (Ellis et al., Nature Reviews Neuroscience 2007) 
 
On the other hand, conflicting studies have demonstrated that even in patients 
initiating therapy during acute infection, immune activation is still evident in the 
CNS after more than four years of effective cART [93], with brain tissue 
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expression of more than 100 genes with roles in adaptive immunity, interferon 
signaling, cell cycle and myelin pathways remaining dysregulated [94].   
Moreover, despite effective cART regimens, undetectable viral loads, and having 
no neurological symptoms at the time of death, 80-90% of HIV+ individuals have 
evidence of neuronal injury and loss, myelin pallor, and elevated numbers of 
activated and productively infected macrophages in the CNS upon examination 
at autopsy [95,96].  Thus, while there remain no established cART guidelines for 
HAND, it is evident that future treatment will require adjunctive therapies that 
target macrophage infection and impede the cascade of inflammatory events that 
result from and perpetuate HIV infection in the CNS. 
 
II.  Simian Immunodeficiency Virus 
A.  SIV and emergence of AIDS in SIV infected macaques  
Soon after the HIV epidemic began, simian immunodeficiency virus (SIV) 
was fortuitously transmitted from sooty mangabys (Cercocebus atys; SIVsm) to 
rhesus macaques (Macaca mulatta; SIVmac) at multiple primate research 
centers in the United States, resulting in AIDS-like disease [97,98].  One feature 
that initially distinguished the HIV and SIV lentiviruses from other retroviruses 
was the number of genes in their viral genomes [99].  Retroviruses are typically 
capable of replication with just the env, gag, and pol genes, however HIV and 
SIV also contain regulatory (tat, rev, and nef) and auxiliary (vif, vpr, and vpu or 
vpx) genes, rendering them much more virulent and pathogenic than most 
retroviruses [100,101].  HIV type 1 (HIV-1) was the first lentivirus identified in 
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humans, and is responsible for the vast majority of infections worldwide [102].  
HIV type 2 (HIV-2) is less easily transmitted and less pathogenic than HIV-1, and 
is predominantly found in western Africa [103].  HIV-2 is most closely related to 
SIVsm and SIVmac, while HIV-1 likely evolved from chimpanzee SIV (SIVcpz) 
[104].  Sooty mangabeys and African green monkeys (Chlorocebus sabaeus) are 
natural hosts to SIV, and thus have low levels of immune activation with viral 
infection and do not develop AIDS [105,106].  On the other hand, Asian primates 
such as the rhesus, pigtailed (Macaca nemestrina), and cynomolgus (Macaca 
fascicularis) macaques are unnatural hosts of SIV, with exposure to the virus in 
these species resulting in a disease course very similar to that seen in humans 
with HIV [107].  Because HIV and SIV are closely related in their genetic 
structure and pathogenicity both viruses induce persistent infection, resulting in 
immune deficiency, progressive wasting, neurodegeneration, opportunistic 
infections, and ultimately death [108,109].  Since the discovery of HIV, 
experiments studying infection in Asian primates have consistently corroborated 
what is seen with HIV-1 infection, and have greatly expanded our understanding 
of HIV pathogenesis.   
B.  Utility of SIV infected macaques in understanding acute HIV 
infection  
Because there is significant viral replication and depletion of immune cells 
early in HIV infection, it is critical that the effects of HIV pathogenesis on the 
GALT, as well as the role of aberrant GI tract activation in subsequent 
neuropathology, be more closely examined.  Yet, it is difficult to monitor changes 
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occurring during acute disease as seroconversion can happen without patients 
even knowing that they are infected.  It is also important to consider that if 
recently identified as HIV-positive, someone will be dealing not only with the 
physical symptoms of acute infection, but with the emotional stresses that come 
along with this type of diagnosis, making it challenging to obtain essential gut 
biopsies or to study CNS effects.  For this reason, SIV infected macaque models 
have been indispensable to research progress, providing important insights into 
the early stages of HIV infection and how these events affect overall outcomes 
[110].  Unlike human patients, tissues can be obtained at any point SIV infection, 
allowing researchers to characterize the cellular components and their roles in 
various tissues at different periods throughout infection, thus providing highly 
useful model of early HIV infection in the CNS, the formation of viral reservoirs, 
and the pathogenesis of disease.  
High numbers of SIV-infected monocytes and macrophages populate the 
bone marrow by 3 days post infection (dpi) and persist throughout acute 
infection, whereas low-to-no infected CD3+ T lymphocytes are evident in the 
bone marrow during this time [111].  In general, there are higher numbers of 
monocytes in the blood of SIV infected macaques than in HIV infected humans, 
and as a primary target of SIV, monocytes and macrophages are an important 
contributor to the dissemination of virus in tissues during early infection [112].  
Viral RNA is found in T lymphocytes and macrophages resident to the small 
intestine by 2-3 dpi [113-115], with significantly increased production of 
proinflammatory cytokines in the gut evident by 6-10 dpi [116].  Similar to HIV-
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infected individuals, the majority of CD4+ T cells are massively infected and 
depleted from the intestinal compartment within weeks of exposure to SIV [50].  
Early damage to the gut mucosa results in increased translocation of microbial 
products into the circulation, driving immune cell activation in the periphery.  
From 2-3 wpi, mucosal tissues are responsible for the generation of SIV-specific 
CTL responses [117].  Comparable to what is seen in humans, SIV infected 
macrophages can be detected in the GI tract throughout the course of disease 
[118], while numbers of macrophages in gut tissues predominate during acute 
infection and with progression to AIDS [119].   
C.  A SIVmac251 infected, CD8 lymphocyte depleted rhesus macaque 
model of rapid neuroAIDS 
Intravenous (iv) inoculation of rhesus macaques with SIVmac251 typically 
results in progression to AIDS within 1-3 years, with 30-40% of animals 
developing SIV encephalitis (SIVE) [120].  Treating SIV infected macaques with a 
chimeric humanized mouse anti-CD8 monoclonal antibody on 6, 8, and 12 days 
post infection (dpi) results in depletion of lymphocytes and natural killer cells and 
leads to a significant elevation in plasma viremia by 12 dpi, providing an excellent 
model of rapid CNS disease [121,122].  Animals that are depleted long-term (> 
28 days of CD8 depletion) develop AIDS within 3-4 months post infection, and 
SIVE is evident in more than 75% of macaques [120,123].  SIV infected rhesus 
macaques develop cognitive, motor, and behavioral deficits with CNS infection 
that resemble neuropsychological changes observed in HIV+ individuals 
[124,125].  Moreover, accompanying neuropathology is analogous to what was 
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observed pre-ART in HIV infected patients with HIVE, including cerebral atrophy, 
neuronal damage, microglial nodules, multinucleated giant cells, productive 
infection in macrophages, and white matter disease, though more acute and 
severe in macaques [120,126].  The rapid progression and comparable nature of 
CNS disease in SIVmac251 infected, CD8 depleted rhesus macaques provides 
an ideal model for the identification and examination of therapeutics that could be 
beneficial for the treatment of HIV infection and the targeting of viral reservoirs in 
the brain.  
 
III.  Immune regulation in the Central Nervous System 
A.  The Central Nervous System as an immune privileged site 
The CNS has long been considered an immune privileged site [127].  It is 
not thought to have a lymphatic system, and is protected by both an endothelial 
blood-brain barrier (BBB) and an epithelial blood-cerebrospinal fluid (CSF) 
barrier.  Interactions between tight junctional proteins expressed by endothelial 
cells and astrocytic foot processes cover the entire surface of brain capillaries, 
regulating and restricting movement of cells and macromolecules across the 
BBB.  Under normal conditions, the number of cells traversing the BBB and 
entering the CNS is very low [128,129], however there are four types of 
mononuclear phagocyte lineage cells in the CNS that are capable of antigen 
presentation, namely parenchymal microglia, meningeal macrophages, choroid 
plexus macrophages, and perivascular macrophages [130].  Microglia, the 
resident CNS macrophages, are yolk sac derived and arrive in the brain during  
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embryonic development and for a brief time postnatally [131].  Microglia are 
rarely turned over by cells from the bone marrow [132], though some research 
suggests they may stimulate B cell and T cell populations under certain 
conditions [133].  In response to activation, microglia undergo morphological 
changes, as well as produce proinflammatory chemokines, cytokines, and other 
soluble mediators that negatively affect neuronal function [134].  Perivascular 
macrophages are distinct from microglia and other CNS mononuclear lineage 
cells in that they are phagocytic in the absence of inflammation [135].  Due to the 
way perivascular macrophages are strategically situated between glial and 
endothelial basement membranes, they are capable of responding to changes 
within the brain and in the periphery [136].  These cells constitutively express 
receptors for antigen recognition (DC-SIGN, mannose receptor) [137], antigen 
presentation (major histocompatibility complex (MHC) II) [138], and several 
receptors for pathogen-associated molecular patterns (PAMPs).  Importantly, 
perivascular macrophages and very highly activated microglia [139] express the 
haptoglobin-hemoglobin complex receptor CD163, allowing these cells to 
scavenge iron complexes in the blood [135]. 
B.  CNS Perivascular Macrophages are turned over by bone marrow 
derived cells 
Early studies in rats approximated that every three months, 30% of 
perivascular macrophages are repopulated by bone marrow derived monocytes 
migrating into the CNS from the circulation [140].  Moreover, in response to 
inflammation, there is increased release of monocytes out of the bone marrow  
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[141], and the rate of perivascular macrophage cell turnover is accelerated [142].  
In the bone marrow, CD34+ myeloid progenitor cells undergo three stages of 
differentiation (monoblast, promonocyte, monocyte) to become mature CD14+ 
monocytes [143].  As part of normal immune surveillance, CD14+ monocytes 
continuously leave the bone marrow, circulate in the blood for 3-5 days, and 
enter tissues where they differentiate into macrophages and myeloid dendritic 
cells [144].  By transplanting autologous EGFP-expressing bone marrow 
progenitor cells into healthy rhesus macaques, our lab conclusively established 
that CD163+ perivascular macrophages are slowly turned over by bone marrow 
derived monocytes [145].  Four years after transplantation, a significant number 
of blood monocytes remain EGFP+, and all EGFP+ cells in the CNS are CD163+ 
perivascular macrophages found in the cerebrum, cerebellum, and choroid 
plexus.  Furthermore, there was a direct relationship between the percent of 
EGFP+ monocytes in the blood and the percent of EGFP+ perivascular 
macrophages in the CNS [145], indicating that the rate of perivascular 
macrophage turnover is dictated events including viral infection and heightened  
immune activation in the periphery [146]. 
C.  Relationship between myeloid cell turnover and CNS disease 
progression 
Similar to what was achieved through the transplantation EGFP-
transduced CD34+ cells in rhesus macaques, the thymidine analog 5’-bromo-2’-
deoxyuridine (BrdU) has been used to precisely quantify the kinetics of monocyte 
traffic out of the bone marrow, through the blood, and into tissues [147].  
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Monocytes leave the bone marrow immediately after completing S-phase of the 
cell cycle, and do not divide again in the blood.  BrdU is incorporated into DNA 
during S-phase, and is thus a specific marker for myeloid cells that have 
emigrated from the bone marrow.  Recent studies utilizing BrdU during SIV 
infection have recapitulated what was previously seen in response to 
inflammation in rodents.  In response to SIV infection in rhesus macaques, there 
is increased egress of monocytes from the bone marrow, and these monocytes 
remain in the circulation for a shorter amount of time before entering the CNS 
and other tissues [147-150].  Importantly, the magnitude of BrdU+ monocyte 
turnover is a more accurate indicator of the rate of progression to AIDS than 
plasma viral load or CD4+ T cell count [148].  Furthermore, the degree of BrdU+ 
monocyte expansion directly predicts the severity of SIVE as early as 8, and 
consistently by 27 dpi [150], underscoring the importance of monocyte dynamics 
during acute infection to overall disease outcomes.  
 
IV.  Dynamics of monocyte infection, activation, and traffic during HIV and 
SIV infection 
A.  Monocyte subsets under normal and inflammatory conditions 
Phenotypically independent subpopulations of monocytes exist in the 
blood, and can be delineated based on their size, granularity, expression of 
surface markers, and the types of chemokines and cytokines that they produce 
[151].  The LPS receptor CD14 is expressed to some degree by all circulating 
monocytes.  With the help of the toll-like receptor 4 (TLR4), CD14 binds to LPS, 
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resulting in cleavage of CD14 from the cell and release of both LPS and CD14 
(soluble CD14, sCD14) into the circulation.  In healthy people, CD14+CD16- cells 
make up 90-95% of blood monocytes.  These monocytes express FcγRI (CD64) 
and the MCP-1 receptor C-C chemokine receptor type 2 (CCR2), and release 
cytokines such as IFN-β and IL-10 [152] (Figure 1.5).  The percentage of 
peripheral blood monocytes expressing the CD16 (Fc receptor for 
immunoglobulin G; FcγRIII) receptor is low under normal conditions, but expands 
significantly in several inflammatory states such as atherosclerosis, sepsis, and 
rheumatoid arthritis [153-155].  In response to peripheral immune activation with 
HIV and SIV infection, there is a bi-phasic expansion in the number of CD16+ 
monocytes in the blood, occurring first with high plasma viral load during acute 
infection, and again prior to and with the development of AIDS, when these cells 
can represent up to 40% of the total circulating monocyte population [156-158].  
The CD16 receptor mediates functions such as removal of immune complexes 
and antibody-dependent cell-mediated cytotoxicity (ADCC) [159].  As a result, 
CD14lo/+CD16+ monocytes have a more mature, macrophage-like morphology, 
and are more phagocytic and efficient at antigen presentation than the 
CD14+CD16- subpopulation [151,160].  CD14lo/+CD16+ monocytes strongly 
express CD49d, CX3CR1, and HLA-DR, and produce high levels of inflammatory 
chemokines and cytokines such as IFNγ, IL-1β, IL-6, and TNFα [161-164].  In 
addition, CD14lo/+CD16+ monocytes are immunophenotypically similar to 
perivascular macrophages in the CNS, with the majority CD16+ monocytes 
expressing the haptoglobin-hemoglobin scavenger receptor CD163, and 
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perivascular macrophages expressing CD14 and CD16 [165,166].  Upon 
activation, monocytes and perivascular macrophages can actively shed CD163 
from the cell surface as soluble CD163 (sCD163).  Levels of sCD163 are 
elevated with increased expansion of activated CD14+CD16+ monocytes [167].  
There is also evidence for LPS induction of CD163 shedding [168].  While 
classical CD14+CD16- monocytes are relatively resistant to infection with HIV 
and SIV, CD14+CD16+ monocytes up-regulate expression of the viral co-
receptor CCR5, rendering these activated cells more susceptible to viral infection 
[169,170].  CD16+ cells may also be infected through phagocytosis of IgG coated 
virion immune complexes [171].  Monocytes restrict viral replication, and the viral 
life cycle only goes to completion after monocytes differentiate into macrophages 
[172].   
 
 
 
 
 
 
 
 
Figure 1.5  Monocyte populations in normal and SIV infection states.  
Subpopulations of circulating monocytes display distinct phenotypic 
characteristics and immune functions. 
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B.  Transmigration of monocytes across the blood brain barrier   
 (BBB) 
Interestingly, CD163 expression improves the adherence of activated 
monocytes endothelial cells prior to migration into the CNS [173].  When CD16+ 
monocytes migrate across the BBB, they can acquire a macrophage phenotype, 
which stimulates productive viral replication.  HIV and SIV infection and 
increased release of chemokines and cytokines (IL-1β, TNFα, IFNα) on both 
sides of the activated brain microvascular endothelium recruit circulating CD16+ 
monocytes to the BBB and induce their transmigration into the CNS [174].  The 
process of monocyte extravasation from the circulation into the brain involves 
several players including selectins, integrins, and cell adhesion molecules [175].  
In both physiological and pathological settings, chemokines activate blood vessel 
endothelial cells to up-regulate expression of E- selectin, L- selectin, and P- 
selectin molecules [176].  CD16+ monocytes engage these selectin molecules to 
initiate a rolling movement along the surface of the endothelium [177,178].  Firm 
arrest to the blood vessel wall is triggered by the interaction of integrins including 
lymphocyte function-associated antigen 1 (LFA-1), very late antigen 4 (VLA-4 / 
α4β1), and α4β7 on monocytes with cognate receptors intercellular adhesion 
molecule 1 (ICAM1), intercellular adhesion molecule 2 (ICAM2), mucosal 
vascular addressin cell-adhesion molecule 1 (MAdCAM1), and vascular cell-
adhesion molecule 1 (VCAM1) expressed by the endothelium [179-181].  Lastly, 
intraluminal crawling and diapedesis through transcellular and paracellular routes 
are mediated by the sequential interaction of junctional proteins activated 
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leukocyte cell adhesion molecule (ALCAM), junctional adhesion molecule A 
(JAM-A), platelet endothelial cell adhesion molecule-1 (PECAM-1), and CD99, 
that are expressed on the endothelium and the cell surface, allowing monocytes 
to complete extravasation into the brain [182,183] (Figure 1.6).   
 
 
 
 
 
 
 
 
A 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
Figure 1.6  Monocyte transmigration across the blood-brain barrier. 
Monocyte transmigration is a multistep process, (A) consisting of capture and 
rolling, chemokine-mediated activation of the monocyte and subsequent firm 
arrest, intravascular crawling with the formation of focal adhesions to the 
vasculature, and ultimately, diapedesis.  (B) An enlarged image illustrating some 
of the homotypic monocyte-endothelial cell interactions, which mediate 
diapedesis.  (Williams et al., Journal of Leukocyte Biology 2012) 
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Several proinflammatory chemokines and cytokines have been implicated in the 
traffic of monocytes across the BBB, including MCP-1, CX3C-chemokine ligand 1 
(CX3CL1, also known as fractalkine), CXCL10, and CCL3 (also known as 
macrophage inflammatory protein 1α, MIP-1α).  Production of these inflammatory 
mediators stimulates up-regulation of adhesion molecules by endothelial cells 
[184], allowing for increased binding and transmigration of activated monocytes 
into the CNS [185].  Levels of CCL2, CX3CL1, and CXCL10 in CSF are used as 
biomarkers of HIV and SIV infection in the CNS, as these chemokines correlate 
with the severity of neuropathology.  By the same token, increased recruitment of 
CD16+ monocytes across the BBB is associated with more rapid progression to 
SIVE [150], and high numbers of CD14+CD16+ cells are observed in the brains 
of HIV-positive individuals with HIVE [186]. 
 
V.  HIV and SIV infection of the CNS 
A.  Resident myeloid lineage cells are susceptible to infection 
While parenchymal microglia, meningeal macrophages, choroid plexus 
macrophages, and perivascular macrophages all express viral co-receptors and 
can be infected [187,188], perivascular macrophages are a consistent target for 
the HIV and SIV in the CNS [135,189,190].  There are increased numbers of 
perivascular macrophages in the brain with HIV and SIV infection [191-193], and 
productively infected CD163+ cells are present throughout the CNS during acute 
disease and with progression to AIDS [135,194,195].  In humans and rhesus 
macaques, expression of CD16+ and CD68+ on activated resident macrophages 
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and microglia is also up-regulated during CNS viral infection [196-198].  In 
addition, HIV and SIV infection of CNS perivascular macrophages and microglia 
stimulates the production of macrophage colony stimulating factor (M-CSF), a 
pro-survival cytokine that protects these cells from apoptosis [199].  Release of 
pro-inflammatory chemokines and cytokines by macrophages and microglia 
serves to increase M-CSF production even further, which contributes to up-
regulation of CD4 and CCR5 expression, viral infection, and viral persistence that 
is observed in the brain throughout infection [200,201]. 
B.  Neuronal damage with HIV and SIV infection 
HIV and SIV do not directly infect neurons, however increased production 
of proinflammatory chemokines, cytokines and other excitotoxic factors by 
infected macrophages and microglia all contribute to neuronal injury and death 
[202-205]. Release of inflammatory mediators such as stromal cell-derived factor 
(SDF)-1, TNF-α, MCP-1, IL-1β, and IL-6 in response to inflammation in the CNS 
results in the activation of macrophages and microglia in the surrounding 
environment [206,207].  Several other viral and cellular factors are also released 
from macrophages and microglia in the presence of brain inflammation, including 
viral proteins gp120, gp41, nef, tat, and vpr, platelet activating factor, arachidonic 
acid, quinolinic acid, and nitric oxide, which accelerate damage to neurons and 
result in neuronal apoptosis [202,203,208-213].  These events lead to reduced 
neuronal dendrites and axonal damage, as well as astrocytosis, myelin pallor, 
and increased BBB permeability, which are linked to the severity of 
neuropathology with HIV and SIV infection [214-216].  
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C.  HIV and SIV enter the CNS very early in disease   
It is generally assumed that virus is carried into the brain within infected 
monocytes, but this has not been directly demonstrated.  Free virus may cross 
the BBB through endothelial cells [217] or through the choroid plexus [218,219].  
The sole evidence that virus enters the brain soon after iatrogenic exposure in 
humans came from an unfortunate case of inadvertent inoculation with HIV [195].  
A seronegative man was admitted to the hospital with complaints of left hip pain 
and fever.  To determine whether he had a bone infection, an indium scan was 
ordered.  However, rather than receiving an infusion of his own radiolabeled 
white blood cells (WBCs) prior to the scan, the individual was accidentally 
infused with WBCs from an HIV-infected patient.  The man was treated with a 
host of antiretrovirals within 45 minutes of the infusion, and virus could not be 
detected in the blood of the individual on day 0, 1, or 8, but was present by 14 
dpi.  The patient died from hepatic encephalopathy and hepatorenal syndrome 
on 15 dpi, when examination of CNS tissue revealed perivascular cuffing and 
HIV infected perivascular macrophages in several brain regions [195].  Early 
infection of the CNS was confirmed in SIV-infected rhesus macaques, where 
after only 3-7 days of infection, gliosis, glial nodules, and productively infected 
cells were found in frontal lobes, temporal lobes, and white matter [194,220].  
Later experiments revealed that SIV RNA is only evident during acute infection (7 
and 14 dpi), and in animals that developed SIVE, whereas viral DNA could be 
isolated from brain throughout disease [197] (Table 1.1).   
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  Table 1.1  Assessment of Viral DNA, RNA, and Protein in the CNS as a 
  Function of Time After SIVmac251 Infection.  (Adapted from Williams et al.,  
  Journal of Experimental Medicine 2001) 
 
 
 
This was also observed in pigtailed macaques, with the additional observation 
that levels of SIV DNA remain consistent from acute infection through the 
asymptomatic phase of disease.  Only viral DNA can be isolated from brains of 
asymptomatic HIV-infected individuals [221], and concentrations of HIV DNA 
during this period are generally very low.  With progression to AIDS, however, 
there are high numbers of productively infected cells, and significantly increased 
concentrations of HIV RNA in the brain [222].   
D. Conflicting hypotheses regarding the etiology of neurological 
manifestations  
While HIV and SIV enter the brain soon after exposure to the virus, clinical 
presentation with neurologic syndromes traditionally occurs during the chronic 
stage of disease in individuals that have been HIV-positive for a long time 
[86,88,89,223].  This suggests that viral infection of the CNS is necessary, but 
not sufficient for the induction of neurological sequelae [85].  There are two 
conflicting viewpoints regarding the etiology and progression of CNS disease.  
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The first is the ‘Trojan Horse’ model, which proposes that virus enters the brain 
very early and establishes persistent infection.  During asymptomatic disease, 
latent infection is maintained, and is the source of recrudescing productive 
infection that manifests with high levels of immune activation and progression to 
AIDS.  HIV sequencing studies supporting this view have demonstrated that 
there is compartmentalized and independent evolution of quasispecies in the 
CNS throughout disease, and that these viruses are phylogenetically distinct 
from sequences found in the plasma, spleen, and lymph nodes [224-227].  In 
other sequence evolution studies, lesions in the CNS of HIV-infected patients 
with HAD contain viral RNA that originated in the brain very early after infection 
[228].  These studies reinforce the notion that the virus that infects the CNS early 
is contributing to the progression of HAND seen in late-term infection with AIDS.  
The second is termed the ‘Late Invasion’ model, suggesting that the development 
neuropathology is late in the course of disease and is independent of virus that is 
already in the brain, instead dependent on events occurring in the periphery 
[229].  Support for the ‘late invasion’ hypothesis comes from the repeated 
observation that the presence of viral RNA in the CNS coincides with the bi-
phasic expansion of circulating CD14+CD16+ monocytes with acute infection 
and progression to AIDS [113].  It is possible that during the asymptomatic period 
of disease, reduced inflammation in the periphery results in diminished traffic of 
cells into the brain, leading to suppression of CNS viral replication.  Further 
evidence for the ‘late invasion’ model comes from the identification of a 
population of recently infiltrating MAC387+ macrophages in the CNS that are 
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believed to play an active role in lesion formation and expansion.  Most 
MAC387+ cells are BrdU+, indicating that they have recently emigrated from the 
bone marrow [150,230].  These MAC387+ macrophages express CCR1 and 
migrate into the CNS in response to CCL3 (macrophage inflammatory protein 1-
α, MIP-1α) [231,232].  The majority of MAC387+ macrophages also express 
CD16+, however these cells are not productively infected.  A heterogeneous 
population of activated resident CD68+ macrophages and microglia, CD163+ 
perivascular macrophages, and recently infiltrating MAC387+ macrophages 
composes multi-nucleated giant cells in macaques with SIVE [230].  
Furthermore, the age and severity of a particular lesion can be determined by the 
relative frequency of MAC387+ and CD68+ macrophages composing the lesion.  
MAC387+ cells predominate in animals with mild encephalitis, whereas higher 
numbers of CD68+ macrophages are found in lesions from macaques with 
severe SIVE [230].  This indicates that different types of monocytes and 
macrophages influence the development and severity of CNS lesions and are 
required for the progression of neuropathology.  Recent studies examining viral 
sequence evolution within the CNS compartment have revealed that distinct viral 
variants arising from the periphery seed the CNS throughout the course of 
disease [233,234], implying that there is continuous transmigration of monocytes 
into the brain with HIV and SIV infection.  Phylogenetic analyses have 
demonstrated that viral sequences isolated from deep white matter are most 
closely related to the viral sequences recovered from circulating monocytes just 
five months earlier [235].  This data provides additional evidence for rapid influx 
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of HIV-infected monocytes into the CNS during late-stage disease.  Thus, it is 
possible that an expansion of activated monocytes with AIDS results and 
increased recruitment of monocytes into the brain and is likely playing a 
significant role in the appearance of neurological symptoms late in disease.  
Finally, with antiretroviral treatment, control of viral replication in the blood results 
in the reduction of macrophage activation and neurotoxin production in the CNS 
[236] which has led to a significant decline in the incidence of HAD and HIVE in 
the cART era [237,238].  Overall, these studies indicate that suppression of 
inflammation in the periphery may dictate the severity of neuropathology with HIV 
infection.  
 
VI.  Barriers to HIV eradication  
A.  Latently infected cellular and anatomic reservoirs of viral   
infection 
After proviral DNA is incorporated into the host genome, the production of 
provirus and expression of viral antigens are dictated by the activation status of 
the cell.  If transcription is silent or levels of transcription are very low, the cell 
can maintain infection while subverting immune surveillance [239,240].  There 
are a number of cellular and anatomic reservoirs of HIV and SIV infection that 
are capable of avoiding detection by the innate and adaptive immune systems 
[241,242] (Figure 1.7).  Resting CD4+ T cells and CD16+ monocytes in the 
blood are latently infected [243-247], and these two cell populations harbor 
genetically distinct viral variants [248,249].  In patients on successful cART, 
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replication competent HIV DNA can be isolated from both T cells and monocytes 
in the periphery throughout the course of disease, indicating that despite therapy, 
these cells are capable of maintaining a reservoir of infectious virus 
[224,239,250].  In addition, there is significant evidence to suggest that HIV and 
SIV seed the CNS and the small intestine during acute infection when viral 
reservoirs are first established.  HIV and SIV DNA is found throughout infection in 
perivascular macrophages and microglia in the brain, and in macrophages 
resident to the GI tract [118,198,221].     
  
 
Figure 1.7  HIV’s many reservoirs. 
Beyond lying in wait in dormant memory T cells, HIV may reproduce at a low rate 
in macrophages and dendritic cells.  Further, HIV infected cells in a few parts of 
the body may be physically shielded from the immune system and certain drugs.  
HIV made in cellular and anatomical reservoirs does not reach the blood readily 
in aggressively treated patients but might generate a vigorous infection if 
treatment stops.  (Stevenson, M., Scientific American 2008) 
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Macrophages and microglial cells are unique in that they are capable of 
harboring virus long-term without cytopathic effects, thus contributing greatly to 
the viral persistence throughout disease in these tissues [198,228].  The brain 
and gut are considered anatomic ‘sanctuaries’, because even when virions are 
released from productively infected cells, they typically remain within tissues 
[251,252].   As a result, replication can persist for a long time before changes in 
viral load can ever be detected in the blood [253].  Complications arising 
throughout infection such as treatment interruption, drug toxicity, or when a drug 
is ineffective against newly-emergent strains, can all induce latently infected cells 
to produce infectious virions, ultimately leading to a rebound in viral load [254].  
Even with effective cART, these cells often become infected before therapy is 
initiated.  What is more, by the time an individual becomes symptomatic and 
converts to an HIV-positive status, latently infected cells have already taken up 
residence in the lymph nodes [42], eliminating the possibility of HIV eradication 
using anti-retroviral drugs alone [255].  It is particularly difficult to treat latent 
infection as mechanisms underlying persistence of HIV in the brain and GI tract, 
as well as the cell types responsible for the formation of viral reservoirs early in 
the course of disease have not been elucidated.  However, because monocytes 
and macrophages represent the primary cell type harboring HIV, adjunctive 
therapies targeting these cells may be effective in reducing latent infection in the 
blood and in these tissues.   
B.  Ongoing peripheral immune activation during HIV and SIV   
 infection 
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Despite viral suppression in cART treated patients, innate immune 
activation persists throughout disease.  The numbers of CD14+CD16+ 
monocytes and inflammatory mediators such as MCP-1, sCD14, sCD163, LPS, 
CXCL10, and IL-6 in the blood are significantly higher in HIV+ patients on 
therapy than in seronegative individuals, and are associated with disease 
progression, morbidity, and mortality [71,256-262].  In addition, even in the 
unique cohort of “elite controllers”, or HIV-positive patients who naturally control 
the virus without antiviral drug treatment, have persistently elevated levels of 
proinflammatory monocytes, soluble mediators (sCD14, sCD163), chemokines 
and cytokines [263-265].  As a result, it is evident that identification of and 
treatment with novel therapies that prevent or reverse peripheral immune 
inflammation will be necessary to improve the overall health and longevity of HIV-
infected individuals.   
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Abstract 
Background:  Minocycline is a tetracycline antibiotic that has been proposed as 
a potential conjunctive therapy for HIV-1 associated cognitive disorders.  Precise 
mechanism(s) of minocycline’s functions are not well defined.   Fourteen rhesus 
macaques were SIV infected and neuronal metabolites measured by proton 
magnetic resonance spectroscopy (1H MRS).   
Methods:  Seven received minocycline (4 mg/kg) daily starting at day 28 post-
infection (pi).  Monocyte expansion and activation were assessed by flow 
cytometry, cell traffic to lymph nodes, CD16 regulation, viral replication, and 
cytokine production were studied.   
Results:  Minocycline treatment decreased plasma virus and pro-inflammatory 
CD14+CD16+ and CD14loCD16+ monocytes, and reduced their expression of 
CD11b, CD163, CD64, CCR2 and HLA-DR.  There was reduced recruitment of 
monocyte/ macrophages and productively infected cells in axillary lymph nodes.  
There was an inverse correlation between brain NAA/ Cr (neuronal injury) and 
circulating CD14+CD16+ and CD14loCD16+ monocytes.  Minocycline treatment 
in vitro reduced SIV replication CD16 expression on activated CD14+CD16+ 
monocytes, and IL-6 production by monocytes following LPS stimulation.   
Conclusion: Neuroprotective effects of minocycline are due in part to reduction 
of activated monocytes and monocyte traffic.  Mechanisms for these effects 
include CD16 regulation, reduced viral replication, and inhibited immune 
activation. 
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Introduction 
Human immunodeficiency virus (HIV) infection of the central nervous 
system (CNS) can result in cognitive impairment, behavioral deficits, and motor 
dysfunction.  With the use of anti- retroviral therapy (ART) the incidence of HIV-
associated neurological disease has declined [1].  While ART prolongs health 
and longevity of HIV-infected individuals, the majority of anti-retroviral drugs have 
poor CNS penetration.  As a result, the prevalence of neurologic complications in 
HIV-infected patients continues to rise [2].  Factors mediating inflammatory 
responses outside the CNS likely play critical roles in CNS dysfunction.  
Monocyte/macrophage traffic likely plays a significant role in driving CNS 
neuropathogenesis [3-6].   
Monocyte traffic across the blood-brain barrier (BBB) occurs at a basal 
level that increases with immune activation [7]. Such traffic likely serves as a 
primary route of viral entry into the CNS [8] and regulates the accumulation of 
macrophages in encephalitic lesions, which are the histopathological correlate of 
HIV-associated neurocognitive disorders (HAND).  The majority of monocytes 
express the lipopolysaccharide (LPS) receptor CD14, while only approximately 
ten percent also express the FcγIII receptor CD16 under normal conditions 
[9,10].  Following viral infection, with inflammation, the number of monocytes as 
well as the percentages of activated monocyte subsets increase, resulting in 
increased traffic to and accumulation within tissues including the brain [11,12].  
Once activated, CD14+CD16+ and CD14loCD16+ monocytes express high levels 
of pro-inflammatory cytokines that are linked to the development of HAND and 
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simian immunodeficiency virus encephalitis (SIVE) [12,13].  With HIV and SIV 
infection, the number of CD14+CD16+ monocytes increases [14,15].  HIV and 
SIV DNA and RNA are found in both CD14+CD16- and CD14+CD16+ monocyte 
subsets in acute infection and AIDS.  Viral DNA is consistently found in 
CD14+CD16+ monocytes throughout disease [16,17].  We have shown that 
perivascular macrophages are repopulated from bone marrow in normal rhesus 
macaques [18] and are a primary cell productively HIV and SIV infected in the 
CNS [19,20].  Populations of monocytes are immunophenotypically similar to 
CNS perivascular macrophages; both express CD14, CD16, and CD163.  Thus, 
it is likely that subsets of CD14+CD16+CD163+ monocytes, some of which are 
infected, repopulate CNS perivascular macrophages [6,21].  Thus, therapies 
targeting monocyte/macrophages outside the CNS can potentially affect neuronal 
injury.   
Minocycline, a lipid soluble tetracycline antibiotic that has putative effects 
on immune system cells, fortuitously can also effectively cross the blood brain 
barrier (BBB) into the CNS parenchyma [22].  Several studies established that 
minocycline possesses anti-inflammatory and possibly direct neuroprotective 
properties independent of its antimicrobial effects [23,24].  Animal studies 
indicate minocycline inhibits the production of immune activators by 
macrophages, microglia [25-28], and neurons [25,27,28].  Minocycline inhibits 
activation, proliferation, and viral replication of microglia, macrophages, and 
lymphocytes in vitro [25,26,29,30]. In SIV-infected pigtailed macaques, 
minocycline reduced plasma virus, the pro-inflammatory monocyte 
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chemoattractant protein 1 (MCP-1)/CCL2, and viral DNA in the CNS [25].  
Whether decreased monocyte/macrophage activation by minocycline also plays 
a neuroprotective role via such mechanisms is not well-defined. To date studies 
correlating neuronal injury simultaneously with viral infection and 
monocyte/macrophage activation have not been done.   
Here, we report the effects of minocycline on monocyte/ macrophage 
numbers and activation, and neuronal injury in a pathogenesis study.  We used a 
CD8+ T lymphocyte depletion model of SIV infection in rhesus macaques, which 
results in rapid progression to AIDS (3–4 months) with a high incidence of SIVE 
[31].  Using this model and magnetic resonance (MR) spectroscopy we found 
that minocycline treatment resulted in stable N- acetylaspartate to Creatine 
(NAA/Cr) levels in the brain (representing neuronal protection) compared to non-
treated animals, which continued to decline (consistent with neuronal injury) [32].  
In the current study, using the same cohort and three additional control non-
minocycline treated animals, we report minocycline treatment reduced activation 
of monocytes that inversely correlated with neuronal injury, reduced the 
accumulation of monocyte/macrophages in lymph nodes of treated animals, and 
inhibited the expression of CCR2, CD163, CD11b, and CD64 on monocytes.  
These results suggest that minocycline, by down-regulating CD16 and viral 
replication, inhibiting monocyte activation and immune cell traffic, is 
neuroprotective. 
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Results 
Fourteen animals were SIV-infected and treated with an anti- CD8+ T 
lymphocyte antibody (cM-T807), administered at 6, 8, and 12 days post infection 
(dpi).  Three were transiently CD8+ lymphocyte depleted (≤21 dpi), while the 
remaining eleven were persistently CD8+ lymphocyte depleted (>28 dpi) (Table 
2.1).  Over the course of the study, there were no significant differences in the 
plasma viral load or numbers of monocyte subsets between the transiently and 
persistently CD8 lymphocyte depleted animals.  We have previously shown that 
persistent CD8+ lymphocyte depletion results in rapid AIDS (3–4 months) with a 
high incidence of SIVE (85%) [32,33].  Minocycline (4 mg/kg/day) was initiated 28 
dpi given daily as we previously reported [34].  Animals were sacrificed with the 
development of AIDS or at a previously determined timed sacrifice. Plasma SIV 
RNA peaked at 108 copy eq. / mL by 12 dpi.  Plasma virus decreased by 
approximately one log after 7 days of minocycline treatment and remained at that 
level until sacrifice (Table 2.1). 
Flow cytometric analyses were completed by employing a gating strategy 
where peripheral blood monocytes were initially identified according to forward 
scatter and side scatter properties (Figure 2.1 A) [10,33].  A small population of 
CD14-negative, HLA-DR- negative cells, likely representing lymphocytes or 
dendritic cells, was excluded by gating on all CD14+ HLA-DR+ cells.  Within this 
gate, monocyte subsets were defined by expression of CD14 versus CD16.  The 
absolute numbers of classical CD14+CD162 monocytes were comparable 
between groups prior to and after minocycline treatment (Figure 2.1 B).  The 
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absolute number of activated CD14+CD16+ (Figure 2.1 C) and CD14 loCD16+ 
(Figure 2.1 D) monocytes increased in the untreated group but were significantly 
reduced in minocycline treated animals at all time points.  The median 
fluorescence intensity (MFI) of CD11b, CD163, CCR2, CD64 and HLA-DR on 
monocyte subsets prior to minocycline treatment (day 27) and terminally was 
examined (Table 2.2).  Day 27 was selected because it was a time point 
immediately preceding minocycline treatment and is a point of peak monocyte 
activation.  All markers studied on monocyte subsets from SIV-infected 
macaques without minocycline treatment were increased one to four-fold at 
sacrifice compared to day 27 pi.  In contrast, there was a two to seven-fold 
decrease in MFI expression of CD11b, CD163, CCR2, CD64, and HLA-DR 
between minocycline treated and untreated animals terminally.  Interestingly, the 
MFI of these markers on monocytes from minocycline treated animals terminally 
was very similar to the values found the prior to treatment indicating that 
minocycline treatment reduces monocyte/macrophage activation in vivo. 
Additionally, the MFI for HLA-DR decreased on all monocyte subsets two-fold 
less than the pretreatment values (Table 2.2).  Thus, minocycline treatment 
reduces the expression of several markers critical for monocyte traffic and 
function at late stage of infection, and in the case of HLA-DR is reduced below 
that found prior to minocycline treatment. 
Next, we examined possible correlations between longitudinal changes in 
monocyte numbers and the ratio of N-acetylaspartate to Creatine (NAA/Cr) in 
different brain regions of the same animals with and without minocycline 
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treatment.  The NAA/Cr ratio in the frontal cortex, parietal cortex, white matter, 
and basal ganglia was previously determined and reported [34] where decreases 
were found in all SIV-infected animals prior to minocycline treatment (dpi 27) 
[34].  At four weeks pi, following minocycline treatment, NAA/Cr in treated 
animals was stabilized, whereas untreated animals had a continued decline [34].  
Linear regression analyses revealed a highly significant relationship between the 
absolute number of pro-inflammatory CD14+CD16+ and CD14loCD16+ 
monocytes and NAA/Cr (in all brain regions).  The relationship between 
monocyte subsets and NAA/Cr in the frontal cortex (CD14+CD16+: r2 = 0.59, p = 
0.0004; CD14loCD16+: r2 = 0.45, p = 0.04) representative of the other brain 
regions is illustrated in Figure 2.2.  In the parietal cortex we found: 
CD14+CD16+: r2 = 0.67, p = 0.0003; CD14loCD16+: r2 = 0.55, p = 0.0007.  In the 
basal ganglia we found: CD14+CD16+: r2 = 0.53, p = 0.039; CD14loCD16+: r2 = 
0.26, p = 0.36. In the white matter: CD14+CD16+: r2 = 0.52, p = 0.0012; 
CD14loCD16+: r2 = 0.50, p = 0.0006.  We only found a significant correlation 
between CD14+CD162 monocytes and NAA/Cr in the parietal cortex 
(CD14+CD162: r2 = 0.36, p = 0.02).  Correlations between CD14+CD162 
monocytes in other brain regions were not significant (data not shown).  The 
inverse relationship between activated CD14+CD16+ and CD14loCD16+ 
monocytes with NAA/Cr coupled with the observation that minocycline treatment 
reduces the number of activated monocytes, supports the notion that there is a 
link between alterations of NAA/Cr and the number of activated monocytes. 
We previously reported that none of the minocycline treated animals 
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developed SIVE (defined as the accumulation of monocyte/macrophages, virally 
infected cells, and multi-nucleated giant cells) [35].  Examining axillary lymph 
nodes we found a statistically significant reduction in the relative numbers of 
resident mature CD68+ macrophages (Figure 2.3 A–B, Figure 2.4 A; p = 
0.0023), recently recruited MAC387+ monocytes/macrophages (Figure 2.3 C–D, 
Figure 2.4 B; p = 0.0033), and productively infected SIV p28+ cells (Figure 2.3 
E–F, Figure 2.4 C; p = 0.0070) with minocycline.  This finding is consistent with 
reduced traffic and activation of monocyte/macrophages, as well as productive 
infection in lymph nodes (Figure 2.4 A–C) similar to the decreased infection we 
reported in the CNS [34].   
In vitro experiments were used to determine the effect of minocycline on 
monocyte CD16+ with viral infection. CD16 expression on 
monocyte/macrophages was reduced following10 mM minocycline for 24 hours, 
and was significantly reduced using 20 mM minocycline for 24 hours (Figure 
2.5). By 72 hours of treatment, CD16 expression was significantly decreased on 
minocycline treated cells at both concentrations (Figure 2.5 A–B) while CD14 
expression was unchanged (data not shown).  These data suggest that by down-
regulating CD16, minocycline treatment may prevent differentiation, activation, or 
both on monocyte/macrophages.  Such inhibition of monocyte/ macrophage 
activation or differentiation in vivo may result in decreased replication or 
abundance of CD14+CD16+ target cells for HIV and SIV.  In addition, 20 mM 
minocycline in vitro significantly reduced SIV replication by 
monocyte/macrophages 96 hours post-infection (Figure 2.5 C).  Whether the 
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inhibition of viral replication in monocytes in vitro is due to a block of viral entry or 
post entry event requires further study. Minocycline did not result in monocyte 
cell death as measured by LIVE/DEAD cell staining (data not shown). We note 
that in vitro doses of minocycline used here (10 mM and 20 mM) are similar to 
those found in serum of minocycline treated humans [36].  Collectively, these 
data indicate that both CD16 expression and viral replication are reduced with 
minocycline treatment, consistent with the effects of minocycline observed in 
vivo. 
Further in vitro experiments were completed to determine the effect of 
minocycline on pro-inflammatory cytokine production in response to LPS 
stimulation (Figure 2.6).  The percentage of CD14+ monocytes producing IL-6 
after 3 hours of culture without stimulation was significantly lower with 10 mM (p 
= 0.04) and 20 mM (p = 0.009) minocycline treatment.  Following 3 hours of 
stimulation with 10 ng/mL LPS, the percent of IL-6 producing monocytes was 
significantly lower with 20 mM than with 10 mM minocycline (p = 0.016).  With a 
higher concentration of 100 ng/mL LPS, minocycline treatment at both 10 mM (p 
= 0.058) and 20 mM (p = 0.03) doses significantly inhibited IL-6 cytokine 
secretion in CD14+ monocytes (Figure 2.6).  TNF production in response to LPS 
stimulation was also examined, however there was no significant difference 
between untreated and minocycline treated monocytes following 10 ng/mL or 100 
ng/mL LPS (data not shown). 
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Discussion 
Here, we demonstrate a correlation between expansion of activated 
monocytes and neuronal protection with minocycline in a rapid model of SIV-
neuropathogenesis.  We found decreased traffic of monocyte/macrophages to 
lymph nodes in minocycline treated animals, and in vitro evidence of a down-
regulation of CD16 expression, a marked decrease in viral replication, as well as 
inhibition of IL-6 production following LPS stimulation.  In minocycline treated 
animals we did not observe an expansion of CD14+CD16+ and CD14loCD16+ 
monocytes that was observed in untreated animals with AIDS.  These data 
parallel our previous results showing a direct relationship between the expansion 
of activated monocyte populations and decreased NAA/Cr [34]. 
Although it is difficult to determine the exact timing of CNS pathological 
changes, neuronal injury as measured by decreased NAA/Cr was detected by 
two weeks pi coincident with an elevation in activated CD14+CD16+ monocytes.  
Virus enters the CNS consistently by two weeks pi likely through trafficking of 
monocytes into the brain [33,37].  This appears to be sufficient for the induction 
of neuronal damage.  We observed a decrease in the absolute number of 
monocytes with minocycline treatment with no further CNS damage, supporting 
the notion that monocyte expansion is required to drive disease. 
In previous work, we observed a bi-phasic increase in the number and 
relative percentage of activated monocytes with the second peak occurring with 
peripheral immune system dysfunction and a steep decline in NAA/Cr ratios [32].  
The levels of circulating monocytes in untreated animals followed this well- 
	  	  	  
  72 
described pattern of biphasic monocyte expansion with the development of AIDS, 
but this second peak was not seen in the minocycline treated animals.  In fact 
there was a decrease in the number of such cells as well as the level of immune 
activation and accessory molecules on total monocytes. 
The neuroprotective effects of minocycline confirm previous observations 
by Zink et al. [25] who found decreased activation of tissue macrophages, CNS 
viral load, and severity of CNS disease with minocycline treatment in SIV-
infected pigtail macaques.  Our results extend these findings by demonstrating 
that the effects of minocycline are directly correlated with reduced number of 
activated monocyte/macrophage and decreased activation markers on these pro-
inflammatory cells.  Zink and colleagues also examined alterations in the potent 
monocyte chemoattractant protein (MCP-1) throughout infection and with 
minocycline treatment.  MCP-1 concentration in CSF followed a biphasic pattern 
with elevations during acute infection that declined after 10–14 dpi and again 
increased after four weeks of infection.  In macaques treated with minocycline 
during chronic infection, the second peak in MCP-1 levels in CSF was not 
observed [38].  This is very similar to our observations that minocycline treated 
macaques did not have a second wave of activated CD14+CD16+ and 
CD14loCD16+ monocytes.  In addition, although expression of the MCP-1 
receptor CCR2 was also significantly increased on the pro-inflammatory 
monocytes of untreated animals in our study, we found CCR2 levels remained 
unchanged on activated monocytes from minocycline treated animals, 
suggesting that minocycline may disrupt the recruitment and trafficking of highly 
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activated monocytes into the CNS.  This was further supported by our findings of 
reduced recruitment, viral replication, and activation of macrophages in the lymph 
nodes of minocycline treated animals. 
Classically activated CD14+CD16- monocytes express CD64 (FcγRI), 
CCR2, low levels of HLA-DR, and release cytokines such as IFN-b and IL-10 
[39][38].  In response to inflammation and viral infection, there is an expansion of 
more mature CD14+CD16+ and CD14loCD16+ monocyte populations first with 
acute infection and again with the development of AIDS, when these cells can 
represent up to 40% of the total circulating monocyte population [10,32].  These 
monocytes express high levels of CD11b, CD163, and HLA-DR and release high 
levels of pro-inflammatory cytokines including TNF-α, IFN-γ, and IL-6 [19].  
Interestingly we found minocycline significantly reduced the number of pro-
inflammatory monocytes, but did not affect the number of classical CD14+CD16- 
monocytes.  This may have resulted from suppressed activation and maturation 
of monocytes, down-regulation of CD16 in vivo, and/or decreased turnover and 
trafficking of this subset of myeloid cells from the bone marrow. 
In addition to its anti-inflammatory effects, minocycline inhibits the growth 
of a wide variety of Gram-negative and Gram-positive bacteria.  Following oral 
administration, concentrations of minocycline are highest in the bile and small 
intestine [40].  It is therefore conceivable that in our SIV infection model of rapid 
neuroAIDS, minocycline binds to and eliminates microbial products in the gut, 
resulting in decreased TLR4 signaling and inhibited expansion of highly activated 
CD16+ monocytes.  In this study, we assayed for LPS in plasma, but did not find 
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significant differences in levels of LPS between the treatment groups.  This does 
not rule out that minocycline might directly effect the response of monocytes in 
vivo to translocated bacterial products.  Decreased expression and therefore 
potentially crosslinking of Fcγ receptors (CD16 and CD64) by antibody opsonized 
microbes in minocycline treated monocytes could have resulted in decreased 
transcription of inflammatory genes [41].  Minocycline treatment has also been 
shown to strongly chelate iron, which is an essential nutrient required by bacteria 
to survive and multiply [42]. 
Recent studies by Szeto et al. [43] indicate that by suppressing 
lymphocyte activation, minocycline treatment reduces HIV replication in CD4+ T 
lymphocytes.  We observed a similar effect in CD14+ monocytes in vitro, where 
reduction of viral replication was directly related to the extent of CD16+ 
expression.  It is important to note that the concentrations of minocycline that we 
used in vitro are physiologically similar to those found in humans with 
minocycline treatment [36,44].  These results indicate that the antiviral effects of 
minocycline are linked to its ability to reduce activation of monocytes and their 
permissiveness to viral infection. CD14+CD16+ and CD14loCD16+ monocytes 
are considered to be at an advanced stage of maturation, and it has been 
proposed that these cells are preferentially infected and harbor viral particles 
long-term [16,17,45].  Current evidence suggests that restriction of viral 
replication in less mature CD14+CD16- monocytes is mediated by differentiation-
dependent cofactors such as apolipoprotein B mRNA-editing enzyme 3G 
(APOBEC3G) and APOBEC3A [46].  Upon CD16-mediated activation, the 
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transcriptional activators NF-kβ and C/EBPβ, which are essential factors for viral 
replication in monocytes, are also induced [47].  Based on the results from our 
study, it is conceivable that minocycline treated monocytes display a restriction to 
SIV replication similar to that of classically activated CD14+CD16- monocytes. 
Despite the reported beneficial effects of minocycline in several animal 
models of CNS disease, including ALS [48-50], a recent clinical trial with ALS 
patients found patients deteriorated significantly faster than the placebo control 
group [51].  These results underscore that caution and more studies are required 
before additional clinical work with minocycline.  In addition, this study 
underscores the importance of understanding differences between animal 
models of disease and disease.  Our data support the notion that inhibition of 
monocyte/macrophage activation, and possibly viral infection, correlates with 
neuronal protection assessed by MRS.  Our results suggest that minocycline 
may be beneficial as an adjunctive therapy, to antiretroviral therapies, that are 
less effective in crossing the BBB.  This data was found using an SIV model of 
CNS neuroAIDS, which might more accurately mirror CNS pathology, than 
mouse models of ALS mirror the human disease. 
We report here that suppression of chronic immune activation with 
minocycline treatment results in the reduced expansion of highly activated and 
potentially infected pro-inflammatory monocytes.  Decreased expression of 
receptors such as CD11b, CD16, and CCR2 critical for trafficking of monocytes 
into the brain demonstrates that minocycline prevented the recruitment of these 
highly invasive cells into the CNS. 
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Experimental Procedures 
Ethical Treatment of Animals 
These studies were performed with the approval of the Massachusetts 
General Hospital Subcommittee on Research and Animal Care and the 
Institutional Animal Care and Use Committee of Harvard University.  Animals 
were housed according to the standards of the American Association for 
Accreditation of Laboratory Animal Care.  Treatment of animals was in 
accordance with the Guide for the Care and Use of Laboratory Animals of the 
Institute of Laboratory Animal Resources. 
Animals, SIV infection, CD8+ T lymphocyte depletion, and Minocycline 
treatment 
The cohort of animals used in this study was reported in a recent 
publication of the effects of minocycline on CNS neural metabolites using MR 
spectroscopy [34].  Three additional non-minocycline treated animals were also 
included in the experiments presented here for a total of n=14 animals.  In the 
current manuscript, we report the effects of minocycline on monocytes from 
animals in this cohort, and perform correlations of monocyte numbers vs. n-
acetylaspartate/creatine (NAA/Cr), a marker of neuronal injury.  Fourteen rhesus 
macaques (Macaca mulatta) were intravenously inoculated with SIVmac251 (20 
ng SIV p27; a generous gift from Dr. Ronald Desrosiers, NERPC) as previously 
described [34].  CD8+ T lymphocyte depletion was achieved using cM-T807, an 
anti-CD8+ antibody that was administered subcutaneously (10 mg/kg) on day 6 
post infection (pi) and intravenously (5 mg/kg) on days 8 and 12 pi [31,52,53].  
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Minocycline was orally administered twice daily (2 mg/kg) to seven animals 
beginning four weeks pi and continuing throughout the study [34].  Macaques 
were sacrificed upon development of AIDS or at a predetermined timed sacrifice 
following four weeks of minocycline treatment. 
Viral load, MRI and MRS 
Plasma SIV RNA was quantified using real-time PCR as previously 
described [53].  NAA/Cr measured values using MRI and 1H magnetic resonance 
spectroscopy (MRS) were recently published [34].  Here we correlate the NAA/Cr 
ratios in different brain regions with monocyte activation and the expansion of 
subpopulations. 
Flow cytometry studies of monocytes 
Peripheral blood was drawn on days 27, 6, 8, and 12 pi, and weekly 
thereafter.  Complete blood counts were obtained using a CBC Hematology 
Analyzer (Hema-True, HESKA).  Flow cytometric analyses were performed with 
100 ml samples of blood as previously described [10].  Fluorochrome-conjugated 
primary antibodies including anti-CD3-FITC (SP34-2), anti-CD4-FITC (L200), 
anti-CD14-FITC (M5E2), anti-CD16-PE (3G8), anti- HLA-DR-PerCPCy5.5 (G46-
6), and isotype control anti-IgG1, k-FITC (MOPC-21) all from BD Pharmingen, 
anti-CD64-FITC (22) and anti-CD163-FITC (Mac2-48) from Trillium Diagnostics, 
anti-CD8-PE (DK25; Dako), and anti-CD11b-APC (M1/ 70.15.11.5; Miltenyi 
Biotec) were used.  Samples were fixed in PBS containing 2% formaldehyde, 
acquired on a FACSAria cell sorter (Becton-Dickinson) and analyzed with Tree 
Star Flow Jo version 8.7.  Monocytes are first selected based on size and 
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granularity (FSC vs. SSC).  From this gate, HLA-DR+ CD14+ monocytes were 
selected.  We note all monocytes analyzed by FSC vs. SSC are HLA-DR+.  The 
absolute number of peripheral blood monocytes was calculated by multiplying the 
total white blood cell count by the total percentage of each monocyte subset 
population as determined by flow cytometric analysis. 
Immunohistochemistry 
Axillary lymph nodes were collected in 10% neutral buffered formalin, 
embedded in paraffin, and sectioned at 5 µm.  Tissues were deparafinized, 
rehydrated and incubated with blocking reagents.  Newly infiltrating 
monocyte/macrophages were identified by the expression of myeloid/histiocyte 
antigen MAC387 (MAC387; Dako) [54].  Mature resident monocyte/macrophage 
and microglia were assessed using anti-CD68 (KP1; Dako) [55].  Cells that were 
productively SIV infected were studied using anti- SIV-p28 (MX-0322; Microbix 
Biosystems) [56].  For quantification, at least 3 non-serial axillary lymph node 
sections from each of the fourteen macaques were stained for each marker.  The 
number of MAC387+, CD68+, and p28+ cells was counted from 4 arbitrary fields, 
and the data are expressed as the number of chromogen-positive cells per unit 
area (mm2).  Sections were visualized with a Zeiss Axio Imager M1 microscope 
(Carl Zeiss MicroImaging, Inc.) using a Plan-Apochromat 620/0.8 Korr objective 
and analyzed using Adobe Photoshop v4 software. 
In vitro infection and minocycline treatment  
Peripheral blood mononuclear cells (PBMC) were prepared from EDTA-
coagulated blood obtained from healthy animals by Ficoll density gradient 
	  	  	  
  79 
separation. CD14+ monocytes were isolated using CD14 MACS microbeads 
(Miltenyi Biotec). Isolated CD14+ monocytes (.95% purity) were adjusted to a 
final concentration of 5x105 cells/mL in RPMI 1640 supplemented with 11 g/L 
sodium pyruvate, 10% fetal bovine serum (Atlas Biologicals), and 10 ng/mL M-
CSF (Peprotech Inc).  Using M- CSF all monocytes in vitro were CD14+CD16+ 
prior to minocycline treatment.  Monocyte/macrophages were infected with a 
highly macrophage tropic clone SIV316STOP virus (30 ng of SIV p27; a 
generous gift from Dr. Ronald Desrosiers, NERPC) at 37°C for 24 hours, then 
washed with PBS containing 2% FBS to remove excess virus.  Cells were 
cultured for 24 or 72 hours with 10 mM and 20 mM minocycline (Sigma Aldrich). 
Myeloid markers were assessed by flow cytometry using anti-CD14-Pacific Blue 
(BD Pharmingen; M5E2), anti-CD16-PE, anti-HLA-DR-PerCpCy5.5, and anti-
CD163-FITC antibodies.  Viability of cells was determined using a LIVE/DEAD 
Fixable Dead Stain Kit (Invitrogen).  Viral replication in conditioned media was 
quantified by SIV p27 ELISA (Advanced BioScience Laboratories, Inc). 
IL-6 and TNF induction by monocytes in vitro  
CD14+ monocytes were isolated and cultured as described in the previous 
section at a concentration of 1x106 cells/mL for 16 hours in non-adherent 
conditions at 37°C. Monocyte/macrophages were then incubated for 3 hours at 
37°C with or without 10 ng/mL or 100 ng/mL LPS (Sigma Aldrich), and 10 mg/mL 
brefeldin A (Sigma Aldrich) for intracellular detection of cytokines. After 
stimulation, cells were fixed and permeabilized with BD Cytofix/CytopermTM 
buffer (BD Biosciences) for 20 minutes at 4°C.  Cells were washed and incubated 
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with anti-CD16-PeCy7 (3G8) anti-IL-6-PE (MP5-20F3), anti-TNF-APC (MAb11), 
anti-IgG1, k-APC (MOPC-21), and anti-IgG2a, k -PE (R35–95) all from BD 
Pharmingen, anti-HLA-DR ECD (Immu-357; Beckman Coulter), and anti-CD14-
Pacific Blue antibodies for 30 minutes at room temperature.  Viability of cells was 
determined using a LIVE/DEAD Fixable Dead Stain Kit and dead cells were 
excluded.  Data are expressed as the percent of total monocytes producing IL-6 
or TNF. 
Statistical methods 
We have previously described kinetics of NAA/Cr over time in different 
brain regions of minocycline treated versus non-treated animals [34].  Here we 
used a least-squares means model to identify correlations between our 
previously determined NAA/Cr in different brain regions and the absolute number 
of different monocyte subsets.  This method allows for the correlation of data 
points that are not independent of one another, such as repeated measurements 
of NAA/Cr or monocytes from the same animal.  Cross terms between animals 
and monocytes were performed where a significant cross term indicated that at 
least one animal’s slope ((NAA/Cr) / absolute monocytes) was contrary to a 
randomly chosen reference animal.  If such significance existed, the statistic was 
considered invalid.  Statistical analysis was performed using JMP 7.0 (SAS, 
Cary, NC).  Mann-Whitney U tests were used for all other statistical analyses and 
performed using Prism version 5.0b (GraphPad Software, Inc., San Diego, CA) 
software. 
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Table 2.1 
 
  Note- dpi = days post infection. 
  * Untreated animals time-sacrificed at 6 weeks pi; all other animals sacrificed  
     at 8 weeks pi. 
    a Transiently CD8+ lymphocyte depleted (≤ 21 dpi), persistently CD8+  
   lymphocyte depleted (> 28 dpi). 
    b Viral RNA quantitated using RT PCR and are results of duplicate  
   measurements. 
 
SIV-infected, CD8+ T Lymphocyte depleted animals used in this study 
 
Animal 
no. 
 
Minocycline 
Length of 
infection  
(days) 
CD8+ lymphocyte 
depletion a 
Terminal 
plasma viral 
load (copy 
eq. /mL) b 
74 – 05 None 56 Persistently depleted 5.6 x 107 
79 - 05 None 42* Persistently depleted 6.3 x 107 
156 - 04 None 62 Persistently depleted 3.6 x 108 
346 - 04 None 62 Persistently depleted 6.2 x 108 
307 - 05 None 43* Persistently depleted 6.5 x 107 
118 - 07 None 57 Persistently depleted 1.8 x 108 
121 - 07 None 57 Persistently depleted 2.2 x 108 
94 - 04 Started 28 dpi 60 Persistently depleted 9.0 x 106 
35 - 07 Started 28 dpi 62 Persistently depleted 8.0 x 107 
150 - 04 Started 28 dpi 60 Persistently depleted 8.3 x 107 
150 - 05 Started 28 dpi 55 Persistently depleted 6.3 x 107 
48 - 07 Started 28 dpi 62 Transiently depleted 4.3 x 106 
227 - 04 Started 28 dpi 60 Transiently depleted 8.9 x 106 
258 - 04 Started 28 dpi 62 Transiently depleted 2.7 x 107 
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Table 2.1 SIV-infected, CD8+ T Lymphocyte depleted animals used in this 
study. 
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Figure 2.1 	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Figure 2.1 Minocycline reduces expansion of activated monocytes. 
(A) Flow cytometric analysis of CD14+CD16−, CD14+CD16+, and CD14loCD16+ 
monocyte populations.  Using flow cytometric analyses, monocytes were first 
selected based on size and granularity (FSC vs. SSC).  From this gate, HLA-DR+ 
CD14+ monocytes were selected.  A small population of CD14-negative, HLA-
DR-negative cells, likely representing lymphocytes or dendritic cells, were 
excluded.  We note that all monocytes are HLA-DR+ based on FSC vs. SSC and 
that the number of HLA-DR+ and absolute number of monocytes are equivalent.  
From the CD14+ HLA-DR+ gate monocyte subsets were fractionated based on 
CD14 and CD16 expression.  (B) Comparisons were made between SIV-
infected, CD8+ T lymphocyte depleted animals with (filled symbols) and without 
(open symbols) minocycline treatment. Minocycline treatment was initiated at day 
28 post-infection (start date is marked by a solid vertical line). The absolute 
number of CD14+CD16− monocytes was comparable between groups 
throughout the course of the study. In contrast, numbers of (C) CD14+CD16+ 
and (D) CD14loCD16+ monocytes were significantly higher in untreated animals 
at all points compared to minocycline treated animals. Data points represent the 
mean ± standard error of the mean (n = 7 animals per group until 6 weeks pi 
when two untreated animals were time-sacrificed).  P values were calculated 
using a Mann-Whitney U test.  p < 0.05 *, p < 0.01 **. 
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Table 2.2 
Note- Means are the median fluorescence intensity, MFI, and the SEM is in 
brackets.  P values were calculated by comparing terminal MFI values for 
untreated and minocycline treated animals. MN = minocycline.  * p < .05. *** p < 
.001.  
 
 
 
 
 
 
 
 
ACTIVATION MARKERS ON MONOCYTE SUBSETS  
MONOCYTE  
SUBSET 
DAY 27 (MFI) TERMINAL (MFI) P 
VALUE ALL ANIMALS UNTREATED MN TREATED 
CD14+CD16-     
     CD11b 11085 (5382)  37149 (17100) 10425 (1603) * 
     CD163 3178 (823)  8791 (2600) 3651 (1911) * 
     CCR2 478 (25) 1971 (649) 463 (170) NS 
     CD64 3443 (201)  5746 (842) 3793 (357) * 
     HLA-DR 3964 (950) 5480 (1747) 1754 (972) * 
CD14+CD16+     
     CD11b 11099 (5261) 37560 (16295) 10171 (1184) *** 
     CD163 4156 (1047) 9140 (2381) 3728 (1754) * 
     CCR2 182 (58) 1172 (306) 303 (109) NS 
     CD64 1209 (162) 2175 (419) 1435 (96) * 
     HLA-DR 8060 (1875) 13160 (3689) 4145 (2456) * 
CD14LOCD16+     
     CD11b 2715 (1131) 6807 (2751) 1822 (483) * 
     CD163 1344 (340) 3328 (572)  1214 (642) * 
     CCR2 27 (92) 360 (115) 113 (25) NS 
     CD64 390 (20) 763 (206) 434 (179) NS 
     HLA-DR 6010 (1408) 9247 (3465) 1227 (186) * 
	  	  	  
  87 
Table 2.2 Activation Markers on Monocyte Subsets. 
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Figure 2.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  	  	  
  89 
Figure 2.2 Linear regression analyses reveal significant relationships 
between circulating pro-inflammatory monocytes and NAA/Cr. 
Regression analyses were performed between the absolute numbers of each 
monocyte subset and the percent change in neuronal metabolite values (NAA/Cr) 
in the frontal cortex relative to pre-infection levels for all animals from 28 days pi 
until necropsy. Minocycline treated and non-treated animals were examined at 4 
time-points except for the two animals that were time-sacrificed at 6 weeks pi, 
have three time-points. We found a significant inverse relationship between both 
CD14+CD16+ (B; r2 = 0.59, p = 0.0004) and CD14loCD16+ (C; r2 = 0.45, p = 
0.04) monocytes and decreased NAA/Cr, while no relationship between 
CD14+CD16− monocytes and NAA/Cr levels were observed (A; r2 = 0.30, p = 
0.3776). 
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Figure 2.3 
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Figure 2.3 Reduced CD68+, MAC387+, and SIV p28+ productively infected 
cells in lymph nodes with minocycline treatment. 
Immunohistochemistry was performed to compare CD68+ resident 
macrophages, newly infiltrating MAC387+ monocytes/macrophages, and SIV-
infected cells in the axillary lymph node from untreated and minocycline treated 
animals. A reduced number of resident CD68+ macrophages (A–B) and newly 
infiltrating MAC387+ monocytes/macrophages (C–D) in an axillary lymph node of 
minocycline treated animals (B, D) and an untreated controls (A, C). In addition, 
there was a significantly higher number of productively infected SIV p28+ cells in 
the lymph node of untreated animals (E) compared to minocycline treated 
animals (F). All scale bars are 50 µm. 
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Figure 2.4 
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Figure 2.4 Minocycline reduces the number of CD68+, MAC387+, and p28+ 
cells in axillary lymph node. 
(A) Quantitative analysis of CD68+ revealed significantly fewer CD68+ cells in 
the axillary lymph node of animals that received minocycline as compared to 
untreated controls (p = 0.0023); (B) fewer numbers of newly infiltrating 
MAC387+monocytes/macrophages (p = 0.0033); and (C) a decreased number of 
productively SIV infected p28+ cells (p = 0.0070). Numbers are representative of 
the means from a minimum of twelve fields calculated to represent a single data 
point for each animal. Horizontal bars indicate group mean values and error bars 
indicate the standard error of the mean. P values were determined using a Mann-
Whitney U test. 
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Figure 2.5 
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Figure 2.5 Reduction of CD16 expression and viral replication in CD14+ 
monocytes during in vitro minocycline treatment. 
(A) CD14+ monocytes were infected with SIVmac316STOP virus and cultured 
with M-CSF in the presence or absence of minocycline for 24 and 72 hours.  With 
M-CSF treatment, all monocytes expressed CD14 and CD16 prior to minocycline 
treatment.  By flow cytometry, monocytes were first gated based on size (FSC) 
and granularity (SSC).  From this gate HLA-DR+ CD14+ monocytes were 
selected and CD16 expression on these cells between treatment groups was 
compared.  (B) Histograms represent the median fluorescence intensity (MFI) of 
CD16 from one representative experiment out of three.  Averages of MFI ± 
standard error of the mean in a given treatment group are indicated in the upper 
left hand corner of the graphs.  CD16 expression was significantly higher on 
untreated than 20 µM minocycline treated monocytes at 48 hours pi (p = 0.021).  
Untreated monocytes had significantly higher CD16 expression than both 10 µM 
and 20 µM treated cells at 96 hours pi (p = 0.001).  (C) After 96 hours of 
infection, SIV-p27 was reduced with minocycline treatment, with significant 
differences between control and 20 µM minocycline (p = 0.039).  Studies 
presented here are the results of n = 3 three independent experiments with n = 3 
animals per experiment performed in triplicate wells.  P values were determined 
using a Mann-Whitney U test. 
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Figure 2.6 
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Figure 2.6 Minocycline treatment inhibits induction of IL-6 by CD14+ 
monocytes in vitro. 
CD14+ monocytes were cultured in non-adherent conditions with M-CSF and in 
the presence or absence of minocycline for 16 hours.  IL-6 was induced by LPS 
in the presence of brefeldin A for 3 hours.  The percentage of monocytes 
producing IL-6 was significantly lower with 10 µM (p = 0.04) and 20 µM (p = 
0.009) minocycline than in untreated cells.  With 10 ng/mL LPS, the percent of IL-
6 producing monocytes was significantly reduced with 20 µM as compared to 10 
µM minocycline treatment (p = 0.016).  With 100 ng/mL LPS stimulation, 
minocycline treatment at both 10 µM (p = 0.058) and 20 µM (p = 0.03) doses 
significantly inhibited IL-6 cytokine secretion in CD14+ monocytes.  Data 
presented represent the results of two independent experiments with n = 3 
animals per experiment performed in triplicate wells.  P values were determined 
using a Mann-Whitney U test. 
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Abstract  
SIV-infected monkeys with high plasma virus and CNS injury were treated with 
an anti-α4 blocking antibody 28 days post-infection, and brain and gut infection 
were assessed.  Treatment resulted in stabilization of neuronal injury (NAA/Cr), 
significantly fewer recruited monocyte/macrophages in brain, and decreased SIV 
infection (SIV p28+, RNA+) in brain and gut.  Treatment initiated at the time of 
infection blocked monocyte/macrophage traffic and infection in the CNS, and 
significantly reduced infection in the intestine.  SIV DNA was undetectable in 
brains of five of six animals treated at the time of infection, but proviral DNA in 
guts of treated and control animals was equivalent.  Animals treated at the time 
of infection had low-to-no plasma LPS or sCD163.  Our results indicate that 
monocyte/macrophage traffic late in infection drives neuronal injury and 
maintains CNS viral reservoirs. Furthermore, early leukocyte traffic seeds the 
CNS with virus and contributes to productive infection of the gut.  
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Introduction 
The importance of monocyte/macrophages as a critical cell type bringing 
human immunodeficiency virus (HIV) to the central nervous system (CNS) is 
often assumed [1,2], but has not been directly tested.  Similarly, the function of 
lymphocytes seeding the gut early during infection has not been directly 
assessed.  HIV infection of the CNS is associated with compromised motor, 
behavioral, and cognitive functioning, collectively referred to as HIV-associated 
neurocognitive disorders (HAND) [3].  Neuropathologic correlates of these clinical 
conditions include accumulation of perivascular macrophages, microglial 
activation, decreased synaptic/dendritic densities, neuronal damage and loss [4].  
Combination antiretroviral therapies (cART) restore peripheral immune function 
and control viral replication, however effective cART does not prevent the 
formation of a CNS viral reservoir early in infection [5].  Consequently, 
neuroinflammation remains and neurologic impairment affects the majority of 
HIV-infected individuals [6,7].  Gut-associated lymphoid tissues (GALT) are 
another important reservoir of HIV RNA and DNA that is established during acute 
infection and persists despite long-term effective therapy [8,9].  
Early after exposure to HIV and SIV, virions and infected cells enter the 
gut and infect resident CD4+ T lymphocytes.  These cells harbor virus and 
propagate infection, resulting in CD4+ T cell loss within days [10,11].  With CD4+ 
T cell depletion, there is expansion of activated immune cells and virus in blood 
that can infect draining lymph nodes, brain, and other tissues [12].  CD4+ T cell 
apoptosis during acute HIV and SIV infection is thought to contribute to aberrant 
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immune activation and translocation of microbial products, which can cause 
increased trafficking of monocytes into the CNS.  It is postulated that this is 
closely linked to the development of HAND and SIV encephalitis (SIVE) [13,14].   
  Similar to the gut, SIV and HIV are found in the CNS as early as 3 
[15,16] and consistently by 14 [5,17] days post infection (dpi), and occurs 
concurrently with accumulation of perivascular macrophages, some of which are 
infected [18,19].  Although neurons are not infected, neuronal damage is evident 
even during the acute phase of infection [20-22].  1H MRS is a sensitive method 
of non-invasively measuring neuronal injury by decreased levels of neuronal 
metabolites N-acetylaspartate+N-acetylaspartylglutamate (collectively NAA).  
Neuronal injury (NAA/Cr) correlates with the expansion of activated monocytes in 
the periphery, indicating that neuroinvasion, likely through entry of activated or 
infected monocytes into the brain, is required for CNS pathogenesis [23].  Using 
BrdU, we have shown that the magnitude of blood monocyte expansion by 8 dpi 
is highly predictive of the rate of disease progression and severity of CNS 
neuropathology [24].  It is widely accepted that monocyte/macrophage traffic and 
accumulation in CNS drives neuronal injury, though no study has tested whether 
directly blocking monocyte/macrophage traffic affects neuronal injury, or blocks 
infection of the CNS by HIV and SIV.   
In this study, we used the anti-α4 antibody natalizumab (Biogen Idec), 
which selectively binds the α4 subunit of α4β1 and α4β7 integrins, blocking the 
interaction between α4 and its’ ligands [25].  Natalizumab prevents accumulation 
of leukocytes (B cells, T lymphocytes, and monocyte/macrophages) in the CNS 
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of patients with relapsing-remitting Multiple Sclerosis [26] and small intestine of 
patients with Crohn’s disease [27].  We used natalizumab primarily to assess the 
requirement of monocyte/macrophage traffic on SIV neuropathogenesis, and 
secondarily to assess the impact of SIV pathogenesis in the gut.  To examine the 
requirement of monocyte/macrophages for neuronal injury, macaques were 
treated later in infection (28, 34, and 41 dpi, “late”; n=4) and compared to SIV 
infected non-treated controls (n=4), all sacrificed when they developed AIDS (50 
to 62 dpi).  To determine if leukocyte traffic seeds the brain and gut with virus, 
animals received natalizumab at the time of infection (0, 7, and14 dpi, “early”; 
n=6) and were compared to untreated controls (n=3), all sacrificed on 22 dpi.  In 
late treated animals, we found decreased accumulation of SIV-infected 
monocyte/macrophages in the CNS and stabilization of neuronal injury.  Early 
natalizumab treatment prevented macrophage traffic and infection in the CNS, 
and decreased the number of productively infected cells in the gut.  These data 
underscore the requirement of monocyte/macrophage traffic for neuronal injury 
and maintenance of the CNS lesions, and indicate that early leukocyte traffic is 
critical for seeding the CNS and contributes to seeding of gut with virus.   
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Results  
Natalizumab treatment with ongoing infection stabilizes neuronal injury 
The eight SIV-infected macaques in the later cohort (n=4 natalizumab 
treated, n=4 non-treated) developed AIDS.  One of the four natalizumab treated 
animals and two of four untreated macaques developed SIVE, defined by 
productive virus, multinucleated giant cells, and macrophage accumulation in the 
CNS.  Plasma viral loads in all animals remained high regardless of treatment 
(data not shown).  We assessed the requirement of continuing 
monocyte/macrophage traffic for neuronal injury and maintenance of CNS 
reservoirs with three weekly natalizumab treatments (30 mg/kg) beginning on 28 
dpi, when significant neuronal damage had already occurred [20,21].  Neuronal 
injury (decreased NAA/Cr) was measured in frontal cortex (FC), parietal cortex 
(PC), basal ganglia (BG), and white matter semiovale (WM) of the four 
natalizumab treated and four untreated macaques by MR spectroscopy bi-weekly 
(Figure 3.1).  The mean NAA/Cr ratio declined from pre-infection to 4 weeks post 
infection (wpi) in FC (-13%, p=0.0028), PC (-8.3%, p=0.0016), BG (-9.7%, 
p=0.008), and WM (-8%, p=0.036) of all animals (Figure 3.1 A-D), consistent 
with neuronal damage as previously reported [21,28,29].  Following natalizumab 
treatment, NAA/Cr decreases stabilized in the FC (+0.5%, p=0.89), PC (-3.3%, 
p=0.60), BG (-2.1%, p=0.76) and WM (-5.7%, p=0.046).  In contrast, SIV infected, 
non-treated animals had continued reductions of NAA/Cr in the FC (-13.2%, 
p=0.016), PC (-12.5%, p=0.0008), and WM (-11.9%, p=0.0001), and a trend 
towards decline in the BG (-6.8%, p=0.13) (Figure 1 E-H).  
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Late natalizumab treatment suppresses the traffic and accumulation of SIV 
infected monocyte/macrophages in the brain 
In all brain regions examined (frontal cortex, parietal cortex, occipital 
cortex, brainstem), numbers of SIV p28+ and RNA+ cells were markedly lower in 
late natalizumab treated versus untreated animals (p28+ p=0.0202, RNA+ 
p=0.0005; Figure 3.2 A).  There were significantly fewer activated CD68+ 
resident macrophages (p=0.0017; Figure 3.2 B) and recently infiltrating 
MAC387+ monocytes (p=0.0003; Figure 3.2 C) in late treated macaques.  We 
have previously observed significant numbers of BrdU+ macrophages in the CNS 
of animals receiving BrdU even 24-hours prior to sacrifice [24], yet no BrdU+ 
macrophages were found in brains of animals that received BrdU after 
natalizumab treatment began (33 dpi, 24-hours prior to necropsy) (Figure 3.2 D).  
In animals that received BrdU throughout infection (-9 dpi, 26 dpi, and 24-hours 
prior to necropsy), we found lower numbers of BrdU+ cells in natalizumab treated 
animals versus controls (Figure 3.2 D).  These data demonstrate that 
natalizumab treatment with ongoing infection blocks monocyte/macrophage 
traffic, reduces the CNS reservoir of productively infected 
monocyte/macrophages, and stabilizes neuronal injury.  
 
Reduced accumulation of T lymphocytes, monocyte/macrophages, and 
productively SIV infected cells in the gut with late natalizumab treatment 
In the gut (duodenum, jejunum, colon), there were fewer SIV p28+ cells in 
treated animals (p=0.0187), but no difference in the number of RNA+ cells 
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observed between late natalizumab treated animals and untreated controls 
(Figure 3.3 A).  There were lower numbers of CD68+ macrophages (p=0.0460; 
Figure 3.3 B), MAC387+ monocytes (p=0.0182; Figure 3.3 C), and CD3+ T 
lymphocytes (p=0.0001; Figure 3.3 D) in the guts of natalizumab treated 
macaques, indicating that late treatment was not sufficient to stop viral infection 
that has already occurred, but did reduce subsequent traffic of lymphocytes and 
monocyte/macrophages.  
 
Early natalizumab treatment blocks traffic and accumulation of SIV infected 
monocyte/macrophages in the brain and gut, and bacterial translocation   
Next we sought to determine whether weekly natalizumab treatment at the 
time of infection (“early”) blocks viral seeding of the CNS and gut.  Relative to 
untreated controls (n=3) that were also sacrificed at 22 dpi, there were fewer SIV 
p28+ (p=0.0004) and RNA+ (p=0.0024) cells (Figure 3.2 A), and CD68+ 
macrophages (p=0.0016; Figure 3.2 B) in the CNS of early natalizumab treated 
animals (n=6).  When present, SIV p28+ and RNA+ cells were primarily found in 
vessels outside the parenchyma.  Numbers of MAC387+ cells were lower in 
brains of early treated macaques (p=0.0179; Figure 3.2 C), and recently 
trafficking BrdU+ cells were absent (Figure 3.2 D).  In the guts of animals 
receiving early natalizumab, there was a significant reduction in SIV p28+ 
(p=0.0012) and RNA+ cells (p=0.0013) (Figure 3.3 A).  There were similar 
numbers of CD68+ macrophages in early treated and control groups (Figure 3.3 
B), but lower numbers of MAC387+ monocytes (p<0.0001; Figure 3.3 C) and 
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CD3+ T lymphocytes (p=0.0001; Figure 3.3 D) with natalizumab treatment.  
Interestingly, early treated macaques had significantly lower plasma LPS at 8 
(p<0.0001) and 12 dpi (p=0.0019) than untreated controls (Figure 4 A).  In 
contrast, equivalent LPS levels were seen in late treated and non-treated animals 
(data not shown).  Early natalizumab also resulted in reduced soluble CD163 in 
plasma, with treated macaques exhibiting significantly lower concentrations than 
untreated macaques at 12 (p=0.0488) and 21 dpi (p<0.0001) (Figure 4 B). 
 
Early natalizumab blocks viral seeding in brain, but not in gut and lymph 
nodes 
To determine whether natalizumab treatment on the day of SIV infection 
blocked latent viral infection in brain and gut, we analyzed tissues for SIV gag 
DNA using qPCR.  Proviral DNA was undetectable in brains of five of six early 
natalizumab treated macaques (Figure 5 A).  One animal had a low level of SIV 
DNA that was detected only in brainstem, which may be explained by brainstem 
trauma resulting from a CSF tap.  Although natalizumab significantly reduced the 
number of productively infected cells in the gut, similar numbers of viral DNA 
copies were found in the duodenum and jejunum of natalizumab and untreated 
animals. SIV gag DNA levels were lower in colon with treatment, however this 
difference did not reach significance (Figure 5 B).   
 
Natalizumab treatment does not affect monocyte/macrophage traffic or the 
accumulation of productively infected macrophages in lymph nodes   
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There was elevated SIV provirus in axillary lymph nodes and similar levels 
of SIV DNA in mesenteric lymph nodes of early natalizumab treated relative to 
untreated controls (Figure 5 C), probably reflecting differing degrees of α4β1 and 
α4β7 utilization in these different compartments.  This was not surprising, as 
comparable numbers of SIV p28+ and RNA+ infected cells were detected in 
lymph nodes from treated and untreated animals in both late and early cohorts 
(Figure 6 A).  Natalizumab treated animals had fewer CD3+ T lymphocytes in 
lymph nodes than matched controls (Late p=0.0011, Early p=0.0006; Figure 6 
D), yet similar numbers of CD68+ (Figure 6 B) and MAC387+ monocytes 
(Figure 6 C) were observed in all animals, suggesting that natalizumab did not 
affect immune recirculation in lymph nodes.   
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Discussion 
While it has been suggested that monocyte/macrophage traffic drives 
CNS infection and neuron damage, this has not been demonstrated 
experimentally.  Here, we examined whether continuous neuronal injury with HIV 
and SIV infection depends on monocyte/macrophage traffic, and if cell trafficking 
to CNS and gut is required for viral seeding.  NAA/Cr was monitored throughout 
infection in four SIV-infected rhesus macaques treated with natalizumab 
beginning after 28 days of infection, when significant neuronal injury had already 
occurred.  We have previously shown these decreases to correlate with 
increased monocyte/macrophage activation, accumulation, viral infection, and 
neuronal injury by immunohistochemical and neuropathologic examination 
[10,20,23,30].  Despite significant reductions in NAA/Cr, blocking 
monocyte/macrophage traffic with natalizumab stabilized NAA/Cr declines, 
consistent with limiting further neuronal injury.  Because natalizumab also blocks 
lymphocyte traffic, it is possible that lymphocytes might also play a role in 
neuronal injury, however it has been repeatedly demonstrated that there are low-
to-no CD4+ T cells in the CNS with HIV and SIV infection [22,31,32], and our 
animals were CD8 lymphocyte depleted. 
To determine whether leukocyte traffic is required for initial seeding of 
brain and gut, animals were treated with natalizumab beginning on the day of 
infection.  At sacrifice 22 days later, no SIV p28+ or RNA+ cells were found in the 
CNS, indicating that traffic of monocyte/macrophages from the periphery is 
necessary for initial viral dissemination in the brain.  This is further supported by 
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the absence of SIV gag DNA in brain tissues of five of six natalizumab treated 
animals.  Provirus in the brainstem of the sixth macaque may be a result of a 
CSF tap trauma, and a lower concentration of SIV gag DNA was found in this 
animal than in brains of non-treated controls.  
There were no BrdU+ cells in early or late natalizumab treated animals, 
indicating that α4 blockade was sufficient to prevent BrdU+ 
monocyte/macrophages from entering the brain.  We have previously reported 
that the majority of BrdU+ cells in the CNS of SIV-infected animals are MAC387+ 
[24,33], underscoring the role of recently recruited MAC387+ monocytes in active 
CNS inflammation [22].  The few scattered MAC387+ monocytes and CD68+ 
macrophages seen in brains of treated animals suggests that despite SIV 
infection and CD8 lymphocyte depletion, very little inflammation occurred in the 
CNS following natalizumab treatment.  Blocking leukocyte traffic later in animals 
with ongoing inflammation and lesions reduced inflammation to almost 
undetectable levels.  These observations with low numbers of SIV p28+ and 
RNA+ cells and rapid stabilization of NAA/Cr in the brains of late natalizumab 
treated animals suggest that ongoing traffic maintains not only neuronal injury, 
but also productive infection of the CNS.   
The small intestine is a primary site for SIV infection, with interaction 
between the α4β7 integrin and MAdCAM-1 facilitating traffic of leukocytes [34,35].  
Natalizumab reduced numbers of CD3+ T lymphocytes, MAC387+ monocytes, 
and SIV p28+ cells relative to controls, suggesting that treatment suppressed 
traffic of cells responsible for early viral replication.  It has previously been shown 
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that loss of α4β7HIGHCD4+ T cells in blood is an indication of decreased numbers 
of CD4+ T cells in gut [36].  Whether we directly blocked trafficking of 
α4β7HIGHCD4+ T cells was not assessed.  SIV DNA was detected in gut tissues 
of early natalizumab treated animals, however it is plausible this is non-integrated 
DNA, as very low numbers of SIV p28+ and RNA+ cells were observed in these 
tissues.  Others have demonstrated that with early infection of GALT with ART 
given four hours after infection, there is protection against rapid depletion of 
CD4+ T cells, yet SIV RNA and DNA were detected [37].  Despite high levels of 
SIV provirus in the gastrointestinal tract with natalizumab treatment, productive 
viral infection appeared to be controlled.  This is in contrast to what was seen in 
the CNS, which might be accounted for in part by the BBB.  It is established that 
in the CNS, the BBB controls traffic of cells, which can be blocked by 
natalizumab.  Therefore, blocking α4β1 and α4β7 likely has a more limited impact 
in gut than in the CNS.  It is important to note that the majority of T cells 
trafficking to GALT utilize α4β7, but this is a small population in the blood [35,38].  
The viral envelope protein gp120 can bind to the α4β7 receptor expressed by 
leukocytes homing to the small intestine, which may not affect cell infection, but 
can result in activation and apoptosis of T lymphocytes by HIV and SIV [39].  
This could be why we observed low numbers of CD3+ T cells despite similar 
levels of SIV DNA in the guts of natalizumab treated animals.   
We found low levels of plasma LPS with early natalizumab treatment, but 
no difference with late treatment, suggesting that inflammation in the intestine 
early during infection contributes to mucosal damage and endotoxin 
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translocation.  In addition to inhibiting release of microbial products such as LPS 
from gut, low levels of sCD163 in plasma were also observed.  Because 
significant reductions of chemokine/cytokine production in blood and CSF have 
previously been shown in natalizumab treated patients [40], this may also have 
contributed to an overall reduction in peripheral immune activation, as suggested 
by the reduced sCD163 and chemokine expression on monocyte and T 
lymphocyte populations in blood (data not shown). We found decreases in ex 
vivo transmigration and adhesion of PBMCs from natalizumab treated animals, 
further supporting the diminished ability of cells to traffic to the brain and gut 
(data not shown).    
Similar numbers of MAC387+ and CD68+ monocyte/macrophages in 
lymph tissues of untreated and treated macaques suggest that natalizumab did 
not significantly affect traffic of these cells to lymph nodes, a finding made by 
others using natalizumab in monkeys [41,42].  These same studies also 
demonstrated normal regulatory immune function in natalizumab treated 
macaques, but increased numbers of lymphocyte precursors, 
monocyte/macrophages, and T cells in blood.  We observed a similar expansion 
of CD14+ monocytes, CD4+ T lymphocytes, CD34+ hematopoietic progenitors, 
and CD20+ B lymphocytes, as well as a decline of CD49d (α4 integrin) 
expression in the periphery of all treated animals (data not shown).  It was 
surprising to observe fewer CD3+ T lymphocytes in lymph nodes of both groups 
of natalizumab treated macaques, however this may be explained by higher 
numbers of SIV p28+ and RNA+ cells and elevated SIV DNA copies in lymph 
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nodes, and therefore high numbers of infected leukocytes that are susceptible to 
apoptosis.  Several papers have shown normal lymphoid follicle function and no 
major differences in immune function with natalizumab treatment, as both 
monocytes and T cells use the interaction between leukocyte function antigen 
(LFA) -1 with ICAM-1 or ICAM-2 in order to traffic into high endothelial venules 
[41,43,44].  
Early initiation of effective cART reduces CNS disease [45], suppresses 
virus to non-detectable levels, and reduces HIV transmission, however current 
therapies are not sufficient to eradicate viral reservoirs [46].  Furthermore, many 
cART therapies have low CNS penetration and do not target 
monocyte/macrophages that drive cardiac and CNS pathology.  While we do not 
suggest using natalizumab long-term in HIV-infected patients, one might consider 
whether natalizumab treatment early, in combination with antiretroviral therapy, 
could stop productive infection of the brain and gut, preventing the establishment 
of these tissue reservoirs.  While PML is a concern in patients receiving 
natalizumab for extended periods, all reported incidents have occurred after 
more than a year of antibody treatment.  Additionally, patients with JC viral 
antibodies have received effective natalizumab treatment for more than 245 days 
without the development of PML [47].  Regardless, the experiments described 
here underscore the critical role of monocyte/macrophage traffic in ongoing 
neuronal injury, and establishment and maintenance of viral reservoirs in the 
CNS and intestinal tissues.   
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Supplemental Data 
 
A number of publications have demonstrated normal regulatory immune 
function with natalizumab treatment, but increased numbers of circulating white 
blood cells, monocytes, B cells, and T cells in humans and rhesus macaques 
given the same dose of the antibody that was used in the current study [41,48].  
Therefore, we monitored the frequency and activation status of leukocyte subsets 
in the blood of all antibody treated macaques throughout infection.  In addition, 
for analysis of unbound α4 integrin (CD49d), staining was performed with 
saturating amounts of antibody against CD49d.  Plasma viral loads were also 
measured throughout infection in untreated and natalizumab treated animals.  
Finally, ex vivo experiments were used to elucidate differences in migratory, 
attachment, and adhesion capabilities of cells isolated from natalizumab treated 
and uninfected macaques.   
We found that plasma viral loads in all animals remained high regardless 
of treatment (Figure 3.7).  Flow cytometric analyses comparing cell populations 
at a preinfection timepoint and following the last natalizumab treatment revealed 
several changes in the blood (Figure 3.8).  There was significant expansion in 
the number of CD20+ B lymphocytes (Late p=0.034, Early p=0.004) and CD34+ 
HPSCs (Late p=0.019, Early p=0.008) in both cohorts of natalizumab treated 
animals (Figure 3.8 A-B).  In late treated animals, there were also significantly 
higher numbers of CD4+ T lymphocytes in the blood (p=0.010), while in early 
treated animals there were significantly more circulating CD14+ monocytes 
(p=0.028).  This indicated to us that antibody treatment rendered cells incapable 
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of trafficking from the blood into various tissue compartments.  Of all cell subsets, 
only the percent of CD34+ HPSCs circulating in the blood increased in late 
natalizumab treated animals (p=0.034), whereas there were significant increases 
in the percentage of CD4+ T cells (p=0.019), CD34+ HPSCs (p=0.003), and 
CD14+ monocytes (p=0.008) in the early treated cohort (Figure 3.8 C-D).  It is 
also important to keep in mind that the early natalizumab treated macaques were 
also being CD8 T lymphocyte depleted during the same time, which may have 
affected the percentages of various cell subsets present in the blood.  Following 
treatment initiation in both groups of animals receiving natalizumab we observed 
much lower levels of CD49d surface expression on CD14+ monocytes (Late 
p=0.043, Early p=0.041), CD4+ T lymphocytes (Late p=0.037, Early p=0.008), 
and CD34+ HPSCs (Late p=0.002, Early p=0.0003), as well as on CD20+ B 
lymphocytes from late treated macaques (p=0.009) (Figure 3.8 E-F).  Overall, all 
cells expressed less unbound α4 following treatment, implying successful α4 
integrin antagonism with natalizumab. 
  The ability of natalizumab to prevent PBMC adhesion to the extracellular 
matrix protein fibronectin was measured ex vivo in real time under constitutive 
and inflammatory (phorbol 12-myristate 13-acetate (PMA) induced) conditions.  
PBMCs isolated from the late treated animals prior to natalizumab (27 dpi) 
displayed rapid attachment (initial increase in normalized cell index (NCI) values) 
and adhesion to fibronectin within two hours of adding PMA (Figure 3.8 A).  
Following natalizumab, cells from treated animals exhibited a markedly reduced 
binding capacity.  In the early natalizumab treated group, there were also fewer 
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numbers of cells attaching to the fibronectin matrix after the addition of PMA 
compared to cells from uninfected and non-treated macaques (Figure 3.8 C).  
While attachment (normalized cell index) increased significantly during the first 
two hours after PMA in PBMCs from uninfected controls, there was a lower 
stable NCI in PBMCs from natalizumab treated animals as well as a decline in 
the impedance slope, representing inhibited adherence of cells.  The number of 
attaching and adhering PBMCs following antibody administration in all treated 
macaques was similar (Late, Figure 3.9 B) or even lower (Early, Figure 3.9 D) 
than that of uninfected animals, indicating that natalizumab treatment resulted in 
an impaired interaction between cells and their ligand fibronectin.   
Lastly, to elucidate potential differences in the ability of cells isolated from 
natalizumab treated macaques to traffic in response to chemokine stimulation, 
we compared the capacity of PBMCs to migrate in response to CCL2 (MCP-1), 
CX3CL1 (fractalkine), SDF-1 (CXCL12), astrocyte conditioned media (ACM), and 
CCL7 (MCP-3).  In late treated animals, the response of CD14+ monocytes to 
CCL2 (p=0.0061), CX3CL1 (p=0.0135), ACM (p=0.0169), and CCL7 (p=0.0373) 
was significantly lower after treatment compared to pre-treatment (27 dpi) values 
(Figure 3.10 A), and CD3+ T lymphocyte responsiveness to CCL2 (p=0.0274) 
and CX3CL1 (p=0.0220) was also suppressed (Figure 3.10 B).  In the early 
natalizumab treated group, CD14+ monocyte chemotaxis to CCL2 (p=0.0216), 
CX3CL1 (p=0.0138), ACM (p=0.0320), and CCL7 (p=0.0005), as well as the 
degree of CD3+ T lymphocyte movement towards CCL2 (p=0.0347), CX3CL1 
(p=0.0111), ACM (p=0.0027), and CCL7 (p=0.0003) was significantly inhibited 
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relative to pre-treatment (pre-infection) migration levels (Figure 3.10 C-D).  
There was no difference in monocyte or T lymphocyte migration towards SDF-1 
with natalizumab treatment, as this chemokine regulates leukocyte function 
antigen (LFA) -1 rather than VLA-4 integrin mediated cell migration [49].  
Typically, increased production of chemokines/cytokines CCL2, CX3CL1, 
CCL7, and fractalkine by endothelial cells, macrophages, and astrocytes during 
HIV and SIV infection results in increased recruitment and infiltration of 
monocytes into the brain [50-52], and expression of receptors CX3CL1 
(CX3CR1), CCL2 and CCL7 (CCR2) is elevated on monocytes and T cells 
homing to the small intestine [53].   However, in natalizumab treated patients, 
significant reductions of chemokine/cytokine production in blood and CSF have 
previously been reported [40].  In our study, reduced levels of chemokines and 
cytokines in the blood of the natalizumab treated animals was also observed, and 
may have contributed to an overall reduction in chemokine expression on 
monocyte and T lymphocyte populations in blood.  Decreased activation of 
immune cells with natalizumab treatment likely contributed to the blockade of cell 
traffic into tissues.  This was also observed on functional level in ex vivo 
transmigration and adhesion assays with the continued decline in the capacity of 
PBMCs to employ α4-mediated adhesion and migration under inflammatory 
conditions, supporting the notion that there was also diminished trafficking of 
leukocytes into the brain and small intestine with natalizumab treatment.  
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Experimental Procedures  
Ethical Treatment of Animals 
Animals were housed according to the standards of the American 
Association for Accreditation of Laboratory Animal Care.  The studies were 
performed with the approval of the Massachusetts General Hospital 
Subcommittee on Research and Animal Care, the Institutional Animal Care and 
Use Committees of Harvard University and BIOQUAL, Inc.  The treatment of 
animals was in accordance with the Guide for the Care and Use of Laboratory 
Animals of the Institute of Laboratory Animal Resources (8th edition).   
Animals, SIV infection, CD8 lymphocyte depletion, and viral load 
determination 
A total of seventeen rhesus macaques (Macaca mulatta) were 
intravenously inoculated with SIVmac251 (20ng SIV p27; a generous gift from Dr. 
Ronald Desrosiers, NERPC).  CD8 lymphocyte depletion was achieved using 
cM-T807, an α-CD8 antibody that was administered subcutaneously (10 mg/kg) 
on day 6 post infection (pi) and intravenously (5 mg/kg) on days 8 and 12 pi [54-
56].  Eight macaques (n=4 late natalizumab treated, n=4 untreated) were 
sacrificed at similar time points with progression to AIDS (50 to 62 dpi).  Nine 
animals (n=6 early natalizumab treated, n=3 untreated) were sacrificed at 22 dpi.  
Plasma SIV RNA was quantified in all animals at various time points throughout 
infection using real-time PCR as previously described [56]. 
Anti-α4 integrin (natalizumab) administration  
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The recombinant humanized IgG4 monoclonal anti-α4 integrin mAb 
(natalizumab) was kindly provided by Biogen Idec (Cambridge, MA) in a sterile 
concentrated solution.  This antibody has specificity for the α4 subunit of α4β1 
(very late activation antigen 4, VLA-4) and α4β7 integrins expressed on the 
surface of all leukocytes except neutrophils [51].  The rhesus macaque α4 
sequence exhibits 96% homology with the human sequence (NCBI), and the 
anti-α4 antibody binds to the α4 subunit with affinity comparable to that in 
humans (Kd = 0.04 – 0.07 µg/ml) [41].  The pharmacokinetic half-life of 
natalizumab in humans is 11 ± 4 days, however more than 70% of α4 integrin 
sites remain saturated 4 weeks after infusion and cell counts in the CSF are 
significantly reduced for up to 6 months [57].  The antibody was administered 
once weekly for three weeks beginning on the day of infection (0 dpi, n=6) or 28 
days after infection (28 dpi, n=4).  On the day of infusion 30 mg/kg of α-VLA-4 
was injected into a 250 mL bag of 0.9% NaCl and administered intravenously (iv) 
over 30-60 minutes.  We chose a high dose of natalizumab and only treated 
three times with one-week intervals between each treatment to avoid 
hypersensitivity responses by the monkeys to the humanized antibody.  This 
regimen has previously been shown to maintain high serum levels of natalizumab 
throughout treatment in rhesus macaques [41].  Chemistry panels including 
alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were 
examined at various time points throughout infection and remained below 100 
IU/L, indicating that natalizumab treatment did not induce hepatotoxicity. 
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BrdU administration 
5-bromo-2’-deoxyduridine (BrdU) (Sigma) was prepared as a 30 mg/mL 
stock solution in 1X PBS (Ca2+/Mg2+ free; Mediatech Inc.) and given 
intravenously at 60 mg/kg as described previously[24].  To monitor levels of 
monocyte/macrophage trafficking out of the bone marrow, in blood, and into the 
CNS and gut, BrdU was administered prior to infection (-9 dpi), at peak infection 
(26 dpi), and 24 hours prior to necropsy in two macaques given natalizumab 
beginning on 28 dpi and two untreated control animals.  In the other thirteen 
animals, BrdU was administered once natalizumab treatment was initiated, on 
days 33 and 47 post infection (n=2 late treated, n=2 untreated) or days 6 and 20 
post infection (n=6 early treated, n=3 untreated).  
MRI/MRS 
To determine if blocking monocyte/macrophage traffic impacted neuronal 
injury, n=4 rhesus macaques were treated with natalizumab beginning on 28 dpi.  
These animals and non-treated controls (n=4) were scanned prior to infection 
(2x) and biweekly thereafter until sacrifice.  For imaging, each animal was 
tranquilized, intubated, and monitored continuously throughout the scanning 
procedure as previously described [29,58].  Briefly, MR imaging and 
spectroscopy were performed on a 3 Tesla whole-body imager (Magnetom TIM 
Trio, Siemens) with a circularly polarized transmit-receive extremity coil.  First a 
three-plane localizer scan, used for positioning and to ensure 1H voxel 
reproducibility, was acquired.  The 1H MRS volumes of interest (VOI) were then 
chosen as previously described [29,58].  Single-voxel proton spectra were 
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acquired from the parietal cortex (PC), frontal cortex (FC), basal ganglia (BG) 
and white matter semiovale (WM) using the point resolved spectroscopy 
sequence (PRESS) with WET [59] water suppression.  Spectroscopic data were 
processed using LCModel software and concentrations of NAA (N-
acetylaspartate + N-acetylaspartylglutamate) and creatine-containing compounds 
(Cr) were quantified using the unsuppressed water signal as an internal intensity 
reference.  
Flow cytometry  
Flow cytometric analyses were performed as published [60] using 100µl 
samples of blood stained with the following fluorochrome-conjugated primary 
antibodies: anti-CD3-Alexa Fluor 700 (SP34-2), anti-CD4-PerCp-Cy5.5 (L200), 
anti-CD8-APC (RPA-T8), anti-CD11b-Alexa Fluor 700 (1CRF44), anti-CD14-
Pacific Blue (M5E2), anti-CD16-PE-Cy7 (3G8), anti-CD20-APC (2H7), anti-
CD20-APC-Cy7 (L27), anti-CD25-PE (M-A251), anti-CD34-PE (563), anti-
CD49d-PE-Cy5 (9F10), anti-CD95-FITC (DX2), anti-CD195-APC (3A9), and 
isotype control anti-IgG1, κ-FITC (MOPC-21) from BD Biosciences, HLA-DR-
Texas Red PE (Immu-357; Beckman Coulter), anti-CD163-PerCp-Cy5.5 (GHI/61; 
Biolegend), anti-CD8-PE (DK25; Dako), anti-CD28-PE-Cy7 (CD28.2; 
eBioscience), anti-CD8-Qdot-655 (3B5; Invitrogen), anti-CD44v6-Biotin (VFF-7; 
Invitrogen), anti-CD4-Qdot-605 (19Thy-5D7; NIH Nonhuman Primate Reagent 
Resource), anti-CCR2-PE (48607; R&D Systems), and anti-CD64-FITC (22; 
Trillium Diagnostics).  Samples were fixed in PBS containing 2% formaldehyde, 
acquired on a FACSAria cell sorter (Becton-Dickinson) and analyzed with Tree 
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Star Flow Jo version 8.7.  Monocytes and lymphocytes were first selected based 
on size and granularity using forward scatter (FSC) area vs. side scatter (SSC) 
area.  From this gate, doublets were excluded (FSC area vs. FSC height).  
Populations were further identified using negative selection and positive 
expression of various cell markers using 12-color flow cytometry panels.  
Complete blood counts were obtained using a CBC Hematology Analyzer 
(Hema-True, HESKA) and the absolute number of peripheral blood cell subsets 
was calculated by multiplying the total white blood cell count by the total 
percentage of each population as determined by flow cytometric analysis.  
Median Fluorescence Intensity (MFI) values were calculated by subtracting the 
MFI of the appropriate isotype control.   
Soluble CD163 ELISA and LAL assay for LPS in plasma  
Levels of sCD163 in plasma were determined using an ELISA kit, 
according to the manufacturer’s protocol (Trillium Diagnostics) as previously 
described[24].  Endotoxin lipopolysaccharide (LPS) levels in heat-inactivated 
plasma were measured using the Limulus Amebocyte Lysate (LAL) test 
(Associates of Cape Cod Inc.) as previously described [24].  Samples were 
diluted fivefold with endotoxin-free water and heated (30 min at 65°C) to 
inactivate plasma components.  Following incubation with LAL (30 min at 37°C) 
and chromogen, duplicate samples were read at 570 nm in a photometric plate 
reader.  LPS concentrations were expressed in endotoxin units (EU), with an 
assay sensitivity range of 0.005 EU/mL - 50 EU/mL. 
Cell migration induced by chemokines or astrocyte supernatant 
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Blood from Tysabri treated and control animals was collected into EDTA 
coated vacutainers and peripheral blood mononuclear cells (PBMCs) were 
prepared by Ficoll density gradient separation.  Chemokines and astrocyte 
supernatants were prepared from frozen stocks each day.  Astrocyte 
supernatants were cultured and harvested as described in detail [61,62] and 
warmed to 37°C prior to use.  MCP-3/CCL7 was used at a concentration of 
100ng/mL, SDF-1/CXCL12 at 10ng/mL, CCL2/MCP-1 at 35ng/mL, and CX3CL1 
/fractalkine was used at 90ng/mL (all from R&D systems).  Control ± chemokine 
containing medium or Astrocyte Conditioned medium was added to the lower 
compartment of 3µm pore multiwell insert filters (Becton Dickinson).  100µL of 
106/mL PBMCs were seeded into the upper compartment of the transwell and 
allowed to migrate at 37°C with 5% CO2.  After 2 hours the filters were removed 
and the number and phenotype of cells in the lower compartment was assessed 
by flow cytometry.  Samples of input cells were also stained in all studies to 
determine the ratios of CD14+ monocytes: CD3+ T lymphocytes seeded on the 
transwells.  In the MCP-3, SDF-1, and Astrocyte Conditioned media experiments 
anti-CD3 (FN18, Bioscource), anti-CD11b (Bear1, Immunotech), and anti-CD14 
(M5E2, BD Biosciences) and previously described flow cytometric analyses 
[60,63] were utilized.  For the CCL2 and CX3CL1 transmigration assays, PBMCs 
were stained with anti-CD3-Alexa Fluor 700, anti-CD4-FITC (L200; BD 
Biosciences), anti-CD14-Pacific Blue, anti-CD16-PE-Cy7, anti-CD20-APC (2H7; 
BD Biosciences), and HLA-DR-Texas Red PE using a published protocol [64].   
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Results are expressed as fold change in chemotaxis, which represents the 
difference in PBMC transmigration between basal and stimulated conditions.  
Automated measure of cell adhesion  
The xCELLigence system (ACEA Biosciences) monitors changes in 
electrical impedance across a network of microelectrodes covering the bottom of 
a tissue culture well.  With these changes, the system calculates the Cell Index 
(CI), a dimensionless parameter that is directly proportional to the area of a well 
that is covered by adhering cells.  xCELLigence E-plates were coated with 
10ug/mL of fibronectin (Sigma) for 30 minutes.  Purified PBMCs from Tysabri and 
uninfected macaques were then seeded into wells of the E-plate at a 
concentration of 2x104 cells/well.  After adding cell suspensions to the E-plate, 
adhesion and proliferation of PBMCs was monitored in 15-minute intervals for 
fourteen hours by the xCELLigence system.  PMA (Sigma) was added at a 
concentration of 10ng/mL seven hours after cell seeding in order to induce cell 
adhesion to fibronectin [64].  Using the RTCA Software 1.2 (ACEA Biosciences) 
the Normalized Cell Index was calculated by dividing the CI value at each time 
point by the CI value when PMA was added. 
Immunohistochemistry and In situ hybridization 
On the day of sacrifice, animals were anesthetized with ketamine-HCl and 
euthanized by intravenous pentobarbital overdose.  Axillary lymph node, 
intestinal (duodenum, jejunum, and colon), and cerebral (brainstem, frontal 
cortex, parietal cortex, and occipital cortex) tissues were collected in 10% neutral 
buffered formalin, embedded in paraffin, and sectioned at 5µm.  For 
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immunohistochemistry, tissue sections were deparafinized, rehydrated and 
incubated with blocking reagents.  Mature resident monocyte/macrophage and 
activated microglia were assessed using anti-CD68 (KP1; Dako) and newly 
infiltrating monocytes were identified by the expression of myeloid/histiocyte 
antigen MAC387 (MAC387; Dako) as previously described[33].  T-lymphocytes 
were stained with anti-CD3 (A 0452; Dako) and BrdU+ cells were examined 
using anti-BrdU (Bu20A; Dako) as previously described [24].  Productive SIV 
infection was determined with anti-SIV-p28 (3F7; Fitzgerald Industries 
International) and by in situ hybridization for SIV RNA using anti-digoxigenin 
labeled SIVmac239 antisense riboprobes that span the entire SIVmac genome 
(Lofstrand Labs) as previously described [65].  Hybridization specificity was 
confirmed in each experiment using the SIVmac239 sense probe and matched 
tissue from uninfected rhesus macaques.  For quantification, at least 3 non-serial 
blind-coded sections from all tissues were stained for each marker.  Tissue 
sections were examined with a Zeiss Axio Imager M1 microscope (Carl Zeiss 
MicroImaging, Inc.) using a Plan-Apochromat x20/0.8 Korr objective and 
analyzed by one unblinded and one blinded observer using Adobe Photoshop 
v11.0.2 software.  The minimum number of arbitrary visual fields analyzed in 
each tissue was 24.  From this number a median number of cells per tissue 
region was calculated.  Data are represented as the number of positive cells per 
unit area (cells / mm2).  
Nucleic acid isolation and qPCR for SIV DNA loads in tissues 
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For each tissue examined, ten 15 µm frozen sections were homogenized 
and washed in 1X PBS (Ca2+/Mg2+ free; Mediatech Inc.) prior to genomic DNA 
isolation using the AllPrep DNA/RNA Mini Kit (Qiagen) according to 
manufacturers instructions.  For each sample, 100ng of gDNA was loaded in 
triplicate wells.  The concentration of the gDNA was calculated using the Qubit® 
2.0 Fluorometer (Invitrogen).  A standard curve was added to each PCR plate, 
consisting of a plasmid containing 1 copy of the SIV gag gene that was serially 
diluted from 1e9 copies down to 1 copy per microliter.  Each quantitative PCR 
reaction contained 5µl of a standard serial dilution or sample (diluted to 20ng/µl) 
and 20µl of reaction master mix containing 12.5µl Invitrogen 2x TaqMan® 
Universal Mastermix 2, 2.25µl each of 10uM forward and reverse primers, 
0.625µl of 10µM TaqMan® probe, and 2.375µl of water.  The forward and 
reverse primers ShehuF  5'-AATTAGATAGATTTGGATTAGCAGAAAGC and 
ShehuR 5'-CACCAGATGACGCAGACAGTATTAT and the MGB TaqMan probe 
ShehuP 6FAM-CAACAGGCTCAGAAAA-MGBNFQ were used as described 
previously [66].  The PCR was performed using Applied Biosystems 7500 Fast 
Real-Time PCR System under the following conditions: 95°C 10 min followed by 
45 cycles of 94°C 15 s and 60°C 60 s.  The lowest limit of detection of the assay 
was 50 copies per reaction.  The number of viral gag gene DNA copies per 
100ng of total tissue gDNA was calculated using Applied Biosystems 750 
Software v2.0.5.   
Statistical methods 
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Statistical analyses were conducted using Prism version 6.0 (GraphPad 
Software, Inc.).  To detect significant changes in NAA/Cr metabolite ratios during 
disease progression, analysis of variance with repeated measures (RM-ANOVA) 
was used.  If significant by RM-ANOVA (P < 0.05), Holm-Šídák post-tests were 
used to isolate significant differences between time points and treatment groups.  
All other P values were calculated using Student’s two-tailed, unpaired t tests.  
Statistical significance was defined as P < 0.05.  Data are presented as the mean 
± the standard error of the mean (SEM). 
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Figure 3.1 
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Figure 3.1 Stabilization of neuronal injury in SIV-infected animals following 
natalizumab treatment.  
(A) A decreased NAA/Cr ratio in frontal cortex (FC), (B) parietal cortex (PC), (C) 
basal ganglia (BG), and (D) white matter (WM), was observed in untreated and 
natalizumab treated animals by four weeks post infection (WPI).  Decreased 
NAA/Cr stabilized with natalizumab treatment (indicated by arrows at 28, 35, and 
42 dpi) in the FC (E), PC (F), BG (G), and WM (H).  Each point represents the 
mean ± SEM.  P < 0.05* using Holm-Šídák post-tests following significant 
repeated measures ANOVA. 	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Figure 3.2 Natalizumab treatment blocks the traffic and accumulation of SIV 
infected monocyte/macrophages in the brain.   
(A) Natalizumab treatment on 28 dpi (“late”), resulted in scattered SIV p28+ and 
RNA+ cells in the CNS (frontal cortex, parietal cortex, occipital cortex, brainstem) 
relative to controls, all sacrificed with progression to AIDS. Natalizumab at the 
time of infection (“early”) prevented the traffic of SIV p28+ and RNA+ cells into 
the parenchyma, while several SIV p28+ and RNA+ cells were evident in tissues 
of untreated controls that were all sacrificed on 22 dpi.  (B) Late natalizumab 
treatment resulted in decreased numbers of CD68+ macrophages in the brain 
relative to controls.  Numbers of CD68+ macrophages were significantly reduced 
in the brains of early natalizumab treated animals compared to matched controls.  
(C) Fewer MAC387+ cells were observed in late natalizumab treated macaques 
compared to non-treated animals.  Significantly less MAC387+ monocytes were 
detected in early treated macaques than in untreated controls. (D) To determine 
the timing of monocyte/macrophage egress into the CNS, animals were 
administered BrdU at various time points.  In animals given BrdU after late 
natalizumab treatment had begun (33 dpi, 24-hours prior to necropsy), there 
were no BrdU+ monocyte/macrophages any brain region examined. Lower 
numbers of BrdU+ cells were detected in natalizumab treated than non-treated 
animals that all received BrdU throughout infection (-9 dpi, 26 dpi, and 24-hours 
prior to necropsy).  No recently recruited BrdU+ monocyte/macrophages were 
found in the parenchyma of animals treated with early natalizumab. Scale bars: 
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50 microns. P values calculated using unpaired t tests.  p < 0.05* , p < 0.01**, p < 
0.001 ***. 
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Figure 3.3 
 	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
 
 
 
 
 
 
 
 
	  	  	  
  139 
Figure 3.3 Natalizumab reduces the accumulation of SIV p28+ and RNA+ 
cells, CD3+ T lymphocytes, and MAC387+ monocytes to the gut.   
(A) There are significantly fewer SIV p28+ infected cells in the duodenum, 
jejunum, and colon tissues from late natalizumab treated animals compared to 
untreated animals.  The numbers of SIV RNA+ cells were similar between both 
groups.  Less SIV p28+ and RNA+ cells were detected in guts of early 
natalizumab treated macaques compared to controls. (B) Untreated animals had 
significantly higher numbers of CD68+ macrophages than late natalizumab 
treated animals. There were comparable numbers of CD68+ macrophages in gut 
tissues from early natalizumab treated and non-treated animals. (C) Untreated 
controls had significantly higher numbers of MAC387+ cells in the intestine than 
macaques starting natalizumab late in infection. Natalizumab treatment early 
reduced the number of infiltrating MAC387+ monocytes compared to controls. 
(D) There were fewer CD3+ T lymphocytes in the gut of late and early 
natalizumab treated animals compared to controls. Lines and error bars indicate 
the mean ± SEM for each treatment group.  Scale bars: 50 microns.  P values 
calculated using unpaired t tests.  p < 0.05* , p < 0.01**, p < 0.001 ***, p < 0.0001 
****. 	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Figure 3.4 
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Figure 3.4 Reduced LPS and sCD163 levels in plasma with early 
natalizumab treatment.   
(A) There were high levels of LPS in plasma on 8, 12, and 21 dpi in control 
macaques, with significant differences between natalizumab treated (represented 
by arrows at 0, 7, and 14 dpi) and untreated groups on days 8 and 12 pi. (B) With 
natalizumab treatment, soluble CD163 (sCD163) remained stable throughout the 
study, whereas sCD163 increased significantly in untreated animals at both 12 
and 21 days post infection. Endotoxin (LPS) and sCD163 levels were determined 
in duplicate.  Each point represents the mean ± SEM and p values were 
calculated using unpaired t tests.  P < 0.05*, p < 0.01**, p < 0.0001****. 	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Figure 3.5 
 	  
	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  
 
 
 
 
 
 
 
Figure 3.5 Natalizumab treatment at the time of infection blocks viral DNA 
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expression in brain, but not in gut and lymph nodes.   
(A) SIV gag DNA was undetectable in all but one of the 24 brain tissue samples 
analyzed from animals treated with natalizumab on the day of SIV infection.  (B) 
Similar viral DNA copy numbers were found in the duodenum and jejunum 
tissues of all macaques sacrificed at 22 dpi, regardless of treatment.  The lowest 
concentrations of SIV DNA were present in the colon of natalizumab treated 
animals, in contrast to untreated macaques, which had much higher levels of SIV 
DNA in this region.  (C) The number of proviral DNA copies was higher in the 
axillary lymph nodes of treated than in non-treated animals whereas SIV DNA 
was lower with natalizumab treatment in mesenteric lymph node tissue.  Viral 
DNA copies were measured in duplicate. Each bar represents the mean ± SEM 
for each animal group.  P values calculated using unpaired t tests.  p < 0.01 **.  	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Figure 3.6 There are fewer CD3+ T cells, but not monocyte/macrophages in 
lymph node of natalizumab treated animals. 
(A) There were similar numbers of p28+ and SIV RNA+ cells in the axillary lymph 
nodes of all of animals, regardless of treatment or time of sacrifice.  (B) 
Comparable levels of activated resident CD68+ macrophages were detected in 
all macaques. (C) The numbers of MAC387+ cells were similar in late and early 
treated versus non-treated macaques.  (D) There was a reduction in CD3+ T 
lymphocytes from tissues of late and early natalizumab treated macaques 
relative to untreated controls.  Each point represents the mean number of 
positive cells in the three tissue regions examined from a single animal.  Lines 
and error bars indicate the mean ± SEM for each treatment group.  Scale bars: 
50 microns.  P values calculated using unpaired t tests.  p < 0.05*, p < 0.01 **. 
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Figure 3.7 
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Figure 3.7 Natalizumab treatment does not affect plasma viral load.  
Comparable levels of SIV RNA were seen in early untreated (n=3, open circles) 
and natalizumab treated animals (n=6, filled circles), with no effect of antibody 
administration on days 0, 7, and 14 post infection (dark grey arrows) on the high 
viral loads visible by 8 dpi.  Natalizumab treatment on days 28, 34, and 41 post 
infection (light grey arrows) also did not affect plasma SIV RNA. Moreover, 
sustained concentrations of virus in the plasma of 28 DPI natalizumab treated 
macaques (n=4, filled squares) were even higher than that of untreated animals 
sacrificed with AIDS (n=4, open squares).    
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Figure 3.8 
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Figure 3.8  Increased leukocyte numbers and decreased unbound CD49d 
expression in the circulation of natalizumab treated animals.  
(A)  Examination of immune cell subsets in the blood of macaques prior to and 
following the last natalizumab treatment revealed an approximate doubling of 
CD4+ T cells, CD20+ B cells, CD14+ monocytes, and CD34+ HPSCs, with 
numbers T cells, B cells, and HPSCs reaching significance. (B)  In early animals, 
significantly higher numbers of T cells, monocytes, and HPSCs were retained in 
the periphery following treatment initiation, with the concentration of B cells in the 
blood also trending towards significance.  (C)  Increases in the percentage of 
leukocyte subsets in the blood of late macaques were generally comparable, with 
only the percent of CD20+ B cells increasing after the last treatment.  (D)  There 
was an increased percentage of CD4+ T cells, CD14+ monocytes, and CD34+ 
HPSCs iwith early natalizumab treatment.  (E)  For analysis of unbound α4 
integrin (CD49d) expression, staining was performed with saturating amounts of 
antibody against CD49d.  In late treated animals, pre-infusion (27 dpi) α4 
expression levels differed between leukocyte subsets, with CD14+ monocytes 
and CD34+ HPSCs expressing higher levels of CD49d than CD4+ T cells and 
CD20+ B cells.  Late natalizumab treatment significantly reduced the CD49d MFI 
on all circulating immune cells, indicating successful α4 integrin antagonism. (F)  
Basal α4 integrin expression levels were higher on monocytes and HPSCs than 
B cells and T cells isolated from macaques on the day of SIV infection.  Following 
treatment initiation, we found significantly lower CD49d MFI on monocytes, T 
lymphocytes, and HPSCs.  P values calculated using unpaired t tests. 
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Figure 3.9 
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Figure 3.9  PBMCs have impaired adhesion and attachment capabilities in 
inflammatory conditions following natalizumab treatment. 
Automated analysis of PBMC binding to the ECM substrate fibronectin in real 
time under constitutive and inflammatory (PMA induced) using the xCELLigence 
system.  (A) A representative attachment curve produced by PBMCs isolated 
from SIV infected rhesus macaques on 27 DPI where adhesion and attachment 
to the activated fibronectin matrix on the bottom of the wells is reflected by an 
increase in the Normalized Cell Index (NCI).  There was minimal interaction of 
PBMCs with fibronectin in unstimulated conditions (light purple and peach), 
however there was a quick and drastic increase in cell impedance (pink and 
green) following addition of PMA after approximately 7 hours (black line). (B)  
Maximal NCI values were calculated in uninfected (n=3, white bar), as well as for 
pre-infection (n=2, light grey bar), 27 DPI (n=2, black bar), and following 
natalizumab (n=2, dark grey bar) PBMCs.  (C) An attachment curve 
demonstrating the difference in NCI between PBMCs from uninfected animals 
(red and blue) and following the last natalizumab treatment (pink and green) in 
early treated animals.  Purple, peach, and light blue lines illustrate very little 
PBMC adherence and attachment in unstimulated (- PMA) conditions.  (D) The 
maximal NCI was calculated for PBMCs from uninfected controls (n=5, white 
bar), pre-infection (n=6, light grey bar) and following the last natalizumab 
treatment (n=6, dark grey bar). 
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Figure 3.10 
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Figure 3.10  Migration of CD14+ monocytes and CD3+ T lymphocytes 
towards chemokines/cytokines is inhibited with natalizumab treatment. 
Differences in migratory capabilities of PBMCs isolated from natalizumab and 
uninfected macaques were assessed by their the ability to migrate through a 3 
µm collagen transwell in response to CCL2, CX3CL1, Astrocyte Conditioned 
Media (ACM), SDF-1, and MCP-3 stimulation.  (A) The ability of CD14+ 
monocytes to migrate in response to all chemokines except SDF-1 was higher 
after four weeks of infection (n=4, black) than for uninfected (n=4, white bars) 
and pre-infection (n=4, light grey) cells.  However, there was a significant 
reduction in the ability of monocytes from late natalizumab macaques to migrate 
towards CCL2, CX3CL1, ACM, and CCL7 following the last treatment.  (B) The 
capacity of CD3+ lymphocytes isolated from late macaques to migrate towards 
CCL2 and CX3CL1 was markedly decreased following the last natalizumab 
treatment, however there were no significant changes in T cell migration towards 
the other three inflammatory stimuli examined.  (C) There was a highly significant 
inhibition of monocyte chemotaxis towards CCL2, CX3CL1, ACM, and CCL7 with 
natalizumab beginning on the day of infection (uninfected: n=3, white bars; pre-
infection: n=6, light grey bars; following last treatment: n=6, dark grey bars).  (D) 
T lymphocyte responsiveness under proinflammatory conditions was also 
impacted by early treatment, as cells were much less likely to migrate towards 
CCL2, CX3CL1, ACM, and CCL7 following the last dose of natalizumab.  P 
values calculated using unpaired t tests.  p < 0.05* , p < 0.01 **, p < 0.001***.  
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In the cART era, HIV infection of the CNS can result in the development of 
HIV-associated neurological disorders (HAND) in more than half of infected 
individuals, and the prevalence of HAND continues to rise [1].  Events leading to 
neuronal injury are not well understood, but the presence of activated and 
productively infected macrophages in the CNS are the best correlates of 
neurocognitive decline [2,3].  Additionally, many studies have emphasized the 
relationship between expansion of activated monocytes and the development of 
neurological disease [4-13].  It appears that persistently elevated numbers of 
CD16+ monocytes are more tightly linked to the development of neurological 
symptoms than the number of virally infected cells in the CNS or CSF viral load 
[12,14,15].  Levels of HIV DNA in CD16+ monocytes are also closely associated 
with the severity of neuropathology [16,17].  Yet, while activation of immune cells 
in the periphery is clearly important to the timing of HIV disease progression, the 
precise role of trafficking monocytes in neuronal damage and the development of 
HAND are not well defined.  The central hypothesis addressed in this thesis is 
that ongoing traffic of accumulation of activated monocytes/macrophages is 
essential for CNS pathogenesis with viral infection.  To test this hypothesis, we 
directly examined the effects of both reducing monocyte activation and viral 
infection, and blocking leukocyte traffic, on neuronal injury and the accumulation 
of infected macrophages in tissues.  
Is monocyte activation required for CNS damage? 
 In the second chapter of this dissertation, we hypothesized that decreased 
monocyte activation with minocycline treatment plays a neuroprotective role in 
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the context of rapid SIV infection.  In these experiments, we found that 
suppression of monocyte activation was sufficient to reverse neuronal injury.  
Treatment with minocycline prevented the development of SIVE, reduced 
damage to neuronal synapses and dendrites, and stopped further neuronal death 
[18].  Importantly, the inhibition of monocyte activation that was observed within 
days of beginning minocycline treatment directly correlated with reversal of 
neuronal damage.  From these findings we concluded that diminished monocyte 
activation results in decreased numbers of cells trafficking into the brain and 
reduced neuronal injury.  
 In addition to suppressing monocyte activation, both plasma viral loads and 
the number of virally infected macrophages in lymph nodes were significantly 
reduced in minocycline treated macaques.  We found a similar effect in vitro, 
where minocycline down-regulated CD16 expression, reduced chemokine and 
cytokine production, and suppressed SIV replication in monocytes/macrophages.  
While minocycline was not engineered to have antiviral functions, data suggest 
that minocycline might also control viral replication by binding to the active site of 
HIV integrase, thus inhibiting enzyme function [19].  Additionally, minocycline has 
been shown to directly interfere with the release of infectious virions through 
repression of nuclear factor (NF)-κB activation [20] and to reduce HIV and SIV 
infection through indirect mechanisms.  By preventing the phosphorylation of Iκβ 
kinase (IKKα/β) and inhibitor of nuclear factor-κβ alpha (Iκβα), minocycline 
modifies chemokine (CXCL10, IL-8, MCP-1,MIP-1α) and cytokine (IFN-γ, IL-6, 
and TNFα) production [21].  Minocycline can suppress SIV infection in 
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Box 1. Conclusions from studies in Chapter 2. 
 
•  Ongoing monocyte activation is required for the development of 
neuroAIDS 
•  Decreased activation of monocytes results in lower CNS traffic 
•  Lower plasma viral loads, decreased infection of monocytes, and  
     the ability of minocycline to cross the BBB and modulate changes 
     within the CNS directly may also contributed to the neuroprotective 
     effects observed with minocycline treatment 
 
macrophages and lymphocytes by impeding the activation of p38 mitogen-
activated protein kinase (MAPK) [22], and it was just recently confirmed that 
inhibition of NF-κB and p38 MAPK activation with minocycline serves to diminish 
phosphoinositide 3-kinase (PI3K) / AKT pathway stimulation with viral infection 
[23].  It is possible that lower plasma viral loads and reduced macrophage 
infection in lymph nodes observed in minocycline treated macaques are a result 
of lower numbers of activated CD16+ monocytes that are targets of infection, and 
the diminished ability of already infected cells to replicate virus.   
  
 
 
 
 
 
 
 Following the publication of our results describing anti-inflammatory and 
neuroprotective effects of minocycline in the SIV model of rapid neuroAIDS [10], 
another study in SIV infected macaques provided additional support for the 
beneficial effects of minocycline in the CNS with viral infection. These 
experiments demonstrated that three months of minocycline treatment 
(4mg/kg/day) starting on 12 dpi (acute infection), but not on 21 dpi (asymptomatic 
infection) prevented damage to dopaminergic neurons, dopamine loss, and 
nigrostriatal dysfunction in the CNS [24].  Similar to our findings, this work 
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emphasizes that significant CNS injury is occurs during acute infection.  Our data 
indicated that minocycline treatment during asymptomatic infection stabilizes 
neuronal damage that is already present, while these results imply that neuronal 
deterioration during acute infection can be prevented completely with minocycline 
treatment.  Taken together, these studies suggest that the earlier treatment is 
initiated, the more effective it is at exerting neuroprotective effects.  Overall, our 
findings in Chapter 2 indicate that early infection of the CNS is not sufficient for 
the development of neurological disease by demonstrating that suppression of 
monocyte activation during asymptomatic infection reverses neuronal injury that 
has already occurred, and prevents the development of SIVE.  Based on these 
results, it is reasonable to suggest that reducing monocyte recruitment into the 
brain in HIV-infected individuals with minocycline or similar adjunctive therapies 
could quell macrophage activation and infection, suppress production of 
chemokines and cytokines, and thus inhibit the induction of CNS pathology.   
Is ongoing traffic of leukocytes necessary for HIV-associated pathogenesis 
in the CNS and small intestine? 
 In the third chapter of the thesis, in order to determine whether continuous 
recruitment of cells from the periphery into brain and gut tissues is required for 
SIV-associated damage to these organs, we directly blocked leukocyte trafficking 
with the anti-α4 antibody natalizumab.  Natalizumab has been utilized to prevent 
the accumulation of leukocytes in the CNS of patients with Relapsing-Remitting 
Multiple Sclerosis [25] and the small intestine of patients with Crohn’s disease 
[26], yet no one has used natalizumab in HIV infection or in an animal model to 
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directly assess the requirement of ongoing monocyte traffic on viral 
pathogenesis.  Natalizumab treatment was initiated at 28 dpi (“late”) when CNS 
injury was already evident in SIV-infected animals.  Despite significant damage, 
stopping monocyte migration into the brain stabilized neuronal injury, reduced the 
number of productively infected macrophages, and disrupted CNS lesion 
formation.  These data provide strong evidence that continuous recruitment of 
cells into the brain is critical for the maintenance and progression of 
neuropathology, and that blocking leukocyte migration during chronic viral 
infection is sufficient to prevent further CNS injury.  We were also intrigued to find 
significantly fewer productively infected SIV p28+ and RNA+ cells in the small 
intestines of “late” natalizumab treated relative to untreated macaques, 
suggesting to us that leukocyte trafficking is vital to the propagation of SIV 
replication in the small intestine during infection.  To our knowledge, this is the 
first time that blocking the continuous trafficking of leukocytes has been shown to 
be necessary for the perpetuation of viral infection in both the brain and the gut.   
Is leukocyte traffic required for the initial seeding of brain and gut tissues 
with cell-associated virus?   
In the last set of experiments, we addressed the long-standing question of 
whether leukocyte traffic is required to establish viral sanctuaries in tissues.  We 
found no SIV p28+, RNA+, or DNA+ cells in the brains of natalizumab-treated 
macaques, indicating that “early” treatment was sufficient to prevent CNS 
infection.  Through these experiments, we demonstrated that migration of 
infected leukocytes across the BBB is required for viral infection of the CNS and 
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that during acute disease, monocytes/macrophages play a critical role in the 
formation of a latent reservoir in the brain.  By inhibiting cell traffic on the day of 
infection, we also gained a greater understanding of how the viral sanctuaries in 
the small intestine are initially established.  Comparable concentrations of 
proviral DNA were isolated from the duodenum, jejunum, and colon of all 
animals, suggesting that leukocyte trafficking is not required for the seeding of 
gut tissues with virus.  In general, the mechanisms regulating initial infection in 
GALT are relatively unclear, but seem to depend on the route and site of 
transmission [27].  More than a decade ago, two studies demonstrated that when 
primary transmission occurs across mucosal surfaces, cell-free virus enters the 
gut through transcytosis across intestinal M cells [28,29].  It may be the case that 
cell-free virus was also capable of establishing infection in the GALT following 
intravenous transmission in SIV-infected macaques.  Our results indicate that cell 
migration into the GI tract during acute infection does contribute to significantly 
increased levels of SIV replication, microbial translocation (LPS), and peripheral 
immune activation (sCD163), however.  Importantly, HIV can directly bind to the 
α4β7 on CD4+ T cells [30], and while this binding is not sufficient for viral entry 
[31], it does result in T cell activation and LFA-1 expression, which in turn 
promotes cell-to-cell transfer of HIV and migration of cells across the 
gastrointestinal mucosa [32].  We postulate that natalizumab binding likely 
inhibited the ability of virus to interact with α4β7 expressing CD4+ T cells, 
reducing mucosal activation and LFA-1 mediated cell-to-cell spreading of 
infectious virions, and resulting in significantly reduced numbers of productively 
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Box 2. Conclusions from studies in Chapter 3. 
 
•  Continuous traffic of monocytes/macrophages is required for 
neuronal injury and maintenance of CNS lesions  
•  Early trafficking of leukocytes is critical for seeding the CNS and 
contributes to seeding of the small intestine with cell-associated 
virus 
•  Natalizumab did not prevent viral invasion in the gut, but 
significantly inhibited SIV replication, microbial translocation, and 
immune activation 
SIV p28+ and RNA+ cells present in the gut.   
 
 
 
 
 
 
 
 In summary, our experiments with natalizumab demonstrate that interaction 
between α4 ligands on leukocytes and integrin molecules on endothelial cells is 
necessary for transmigration of virally infected cells into tissues.  These data are 
critical to better understanding how to modulate leukocyte transmigration, and 
highlight the notion that targeting specific interactions (i.e. α4β1 and VCAM1 vs. 
α4β7 and MaDCAM1) may be useful for designing novel adjunctive therapies 
that selectively target infection in protected viral sanctuaries.  We found that 
blocking leukocyte traffic with natalizumab during early infection prevents the 
seeding of brain with cell-associated virus and significantly reduces the number 
of productively infected cells in the gut, suggesting that along with cART, 
natalizumab treatment in HIV+ individuals soon after exposure might prevent the 
development of HIV-associated pathology in these tissues.  In addition to 
preventing the recruitment of cell-associated virus into latent tissue reservoirs, 
our data in “late” natalizumab-treated macaques indicate that even if natalizumab 
treatment is initiated during the asymptomatic period of infection, inflammation 
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and infection in the brain and gut are still suppressed.  Thus, it seems that even if 
HIV is given the opportunity to establish latent infection in the brain and 
gastrointestinal tract of individuals, preventing further traffic of leukocytes with 
natalizumab treatment would still be beneficial for reducing inflammation and 
productive viral replication in these tissues.  Moreover, our ex vivo experiments 
revealed that natalizumab treatment restricted chemotaxis of T cells and 
monocytes towards potent inflammatory cytokines/chemokines, implying that 
natalizumab therapy could also serve to diminish the migration of cells into 
tissues that are typically replenished by leukocytes.  It is possible that keeping 
infected leukocytes in the periphery might also allow antiretrovirals to more 
effectively target these cells.  Because there are no current data to suggest that 
reactivation strategies can rid latently infected monocytes and macrophages of 
virus, preventing activated cells from leaving the blood may be an efficient way to 
combat persistent HIV infection.      
Why are novel therapies needed to target latently infected 
monocytes/macrophages in the CNS and GALT?  
 Despite complete suppression of virus in the plasma, there are several 
factors that are likely contributing to persistent inflammation and infection in the 
CNS with effective therapy [33].  Multiple publications have reported that the 
majority of ART compounds have limited neuropenetrance [34-36], and that CNS 
levels of antiretrovirals below the therapeutic threshold can result in the 
development of drug resistant viral strains [37].  There are some data to suggest 
that treatment with compounds that have the highest CNS penetration (CPE) 
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scores improve cognitive functioning, medication adherence, employment 
outcomes, and overall quality of life [38-41].  However, other studies assessing 
the relationship between CPE and neurocognitive performance have yielded 
inconsistent results [35,42-44].  This suggests that the ability of drugs to enter the 
CNS may not be sufficient to determine efficacy in treating the symptoms of 
cognitive deficits.  In addition, most of the currently available antiretroviral drugs 
that are capable of penetrating the CNS have also been shown to be neurotoxic 
[45,46].  Three recent studies indicate that the ability of an antiretroviral to target 
CNS macrophages is the most accurate indication of how useful it will be in 
treating clinical symptoms of HIV infection in the brain [12,15,47].  These data, 
along with the fact that viral sequences isolated from the brains of HIV infected 
individuals have macrophage-trophic motifs [48,49], clearly demonstrate that in 
order to be effective in the CNS, a therapy will need to target monocytes and 
macrophages.  
Nevertheless, it appears that no existing ART compound sufficiently treats 
HIV infection in these cells [50-54].  Protease inhibitors are frequently prescribed, 
and are effective in stopping the release of infectious virions from productively 
infected macrophages, however this class of drugs is ineffective against latent 
infection, and is generally more useful for targeting infected lymphocytes [55,56].  
Similarly, because nucleoside reverse transcriptase inhibitor (NRTI) activity relies 
on competition with dNTPs for DNA binding, the ability of these drugs to target 
macrophages depends on the activation status of the cell [57].  As a result, these 
drugs are not useful against resting macrophages that contain integrated provirus 
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[50].  The non-nucleoside reverse transcriptase inhibitors (NNRTIs) are another 
commonly used class of antiviral drugs that function by inhibiting viral reverse 
transcriptase activity [51], and are effective in preventing new infection and 
productive viral replication.  Yet, like NRTIs, because NNRTI activity affects 
events occurring upstream of viral integration into the host cell genome, so these 
compounds have also been rendered ineffective against latent infection in 
macrophages [58].  A newer and highly promising drug called raltegravir prevents 
integration of the HIV genome into host cell DNA, and thus is just as potent in 
targeting macrophage infection as it is lymphocyte infection [59].  Additionally, 
raltegravir has been shown to reach therapeutic concentrations in the CSF [60].  
Yet a single mutation in the integrase gene is sufficient to render macrophages 
resistant to drug activity [61].  Overall, of the 27 currently available antiretroviral 
therapies, only a handful can reduce inflammation and prevent viral replication in 
the CNS.  As result, latent infection and activation of CNS macrophages and 
microglial cells persist despite therapy, and contribute significantly to neuronal 
injury and the perpetually increasing prevalence of HANDs [62-64].  
Similar to the CNS, all currently available antiretroviral drugs are 
ineffective against latently infected macrophages in the GI tract [65]. While 
initiating cART within three weeks of exposure to HIV suppresses productive viral 
replication [66] and limits the extent of damage to the gut mucosa [67], starting 
therapy very early does not prevent HIV infection or CD4+ T cell depletion in the 
gut [68].  Even if cART begins during acute infection and is infective long-term, 
concentrations of proviral DNA do not decay [69,70], viral replication persists 
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[71], and numbers CD4+ T cells in the lamina propria are never completely 
restored [72-75].  As a result, novel antiretroviral or adjunctive therapies will be 
necessary to combat perpetual infection and periodic viral replication in the small 
intestine of HIV-infected individuals. 
How is persistent infection in tissue reservoirs preventing eradication of 
HIV from the body? 
Regardless of when cART is started, and despite strict adherence to 
therapy, currently available treatments are not sufficient to completely rid the 
body of HIV, as all compounds are futile against persistent and periodic viral 
replication in T cells, monocytes, and macrophages in the blood, brain, and GI 
tract.  These cellular and anatomic reservoirs of infection remain a source of 
residual viremia throughout the course of infection [76].  Reactivation of these 
perpetuates peripheral immune activation [16,77,78], and supports the continual 
transmigration of cells into the blood and other tissues, providing the body with a 
constant source of new targets for viral infection [79].   
Activation of latently infected leukocytes in the GI tract perpetuates 
mucosal damage, microbial translocation, and contribute to generalized immune 
activation in the periphery [80-82].  What is more, this reservoir of latently 
infected cells in the GALT contain viral sequences with distinct drug resistance 
mutations from the sequences carried by latently infected cells in the blood [83].  
As a result, it is common for infectious particles that are released from the gut 
into the periphery to be impervious to antiretroviral treatment [84].  When 
administered during acute infection, novel therapies such as natalizumab have 
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the potential to decrease gut inflammation and prevent disruptions to the 
gastrointestinal lumen with HIV infection.  Consequently, this treatment could 
prove useful in suppressing chronic peripheral immune activation and the spread 
of infectious virions from the gut into the circulation.  
 Although still the source of some speculation, early studies in rodents 
demonstrated that not only can monocytes emigrate into the CNS, but that 
perivascular macrophages can also traffic back out of the brain [85].  In addition, 
phylogenetic analyses of viral sequences in the brain and periphery have also 
recently confirmed that HIV can transit out of the CNS and reseed the peripheral 
circulation with infection [86].  Analogous to the GALT, viral sequences in the 
brain carry different antiviral resistance mutations than sequences in the 
periphery [87].  It is likely that these drug-resistant strains proliferate and evolve 
in the CNS [88], then proceed to migrate out of the brain and contribute to 
infection in the periphery [89].   
 It is apparent that high levels of inflammation persist in the CNS and gut 
throughout disease and despite cART, implying that infected cells may be leaving 
these compartments and reseeding the periphery with drug resistant virions at 
any point in infection [90,91].  To this end, latent infection in brain and gut tissues 
is a critical barrier to the eradication of HIV [64,92].  The body will not be free of 
infection until the virus can be cleared from infected monocytes/macrophages 
[93], or if novel adjunctive therapies prove to be effective in preventing the 
establishment of tissue sanctuaries in the first place.	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Summary 
In conclusion, the results described in this dissertation provide novel 
clarity around the role of monocyte traffic in the progression of HIV and SIV 
infection.  Our studies emphasize that events during the acute period of disease 
are critical for determining the overall course and severity of pathology.  What is 
more, these data indicate that continuous migration of monocytes into the brain 
and gut throughout infection is necessary to perpetuate damage in these tissues.  
These results provide a deeper understanding of how reservoirs are initially 
established with viral infection, and about the factors underlying viral persistence 
in the small intestine and brain.  While there remain no antiretroviral or adjuvant 
therapies that are designed to treat latently infected monocytes/macrophages, 
the data presented in this thesis underscores the need to specifically target these 
cells. We demonstrated that minocycline and natalizumab inhibit 
monocyte/macrophage infection and impede the cascade of peripheral 
inflammatory events resulting from and perpetuating disease, indicating that 
these therapies have the potential to effectively limit the establishment and size 
of viral sanctuaries.  
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